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The incidence of musculoskeletal diseases is steadily increasing with aging of the
population. In the past years, extracellular vesicles (EVs) have gained attention in
musculoskeletal research. EVs have been associated with various musculoskeletal
pathologies as well as suggested as treatment option. EVs play a pivotal role in
communication between cells and their environment. Thereby, the EV cargo is highly
dependent on their cellular origin. In this review, we summarize putative mechanisms
by which EVs can contribute to musculoskeletal tissue homeostasis, regeneration and
disease, in particular matrix remodeling and mineralization, pro-angiogenic effects and
immunomodulatory activities. Mesenchymal stromal cells (MSCs) present the most
frequently used cell source for EV generation for musculoskeletal applications, and herein
we discuss how the MSC phenotype can influence the cargo and thus the regenerative
potential of EVs. Induced pluripotent stem cell-derived mesenchymal progenitor cells
(iMPs) may overcome current limitations of MSCs, and iMP-derived EVs are discussed as
an alternative strategy. In the last part of the article, we focus on therapeutic applications
of EVs and discuss both practical considerations for EV production and the current state
of EV-based therapies.
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INTRODUCTION
In the past years, the musculoskeletal research field has seen an increased interest in extracellular
vesicles (EVs), due to their prognostic and therapeutic potential. The term EVs describes vesicles
of a broad size range from 30 to 5,000 nm in diameter enclosed by a lipid bilayer. Different types of
vesicles are distinguished based on their biogenesis route (Figure 1A). Apoptotic bodies, sized 800–
5,000 nm, arise from membrane blebbing and fragmentation of apoptotic cells (Xu et al., 2019b).
Microvesicles (MVs), also referred to as ectosomes, microparticles, or shedding vesicles, range
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FIGURE 1 | Biogenesis and content of extracellular vesicles (EVs). EVs are secreted by any cell type. (A) Based on the biogenesis route, different kinds of vesicles can
be distinguished. Apoptotic bodies arise from membrane blebbing of apoptotic cells. Microvesicles derive from outward budding of the plasma membrane, while
exosomes originate from the endo-lysosomal compartment and are released from the cell after fusion of multivesicular bodies with the plasma membrane. (B) EVs are
enclosed by a lipid bilayer and carry membrane lipids and proteins, cytosolic proteins as well as nucleic acids, such as miRNAs and mRNAs. It is widely assumed that
EV cargo mirrors the characteristics of the parent cell. ESCRT, endosomal sorting complexes required for transport.
between 150 and 1,000 nm in diameter and are formed by
outward budding of the cell membrane (Colombo et al., 2014).
Themost homogenous vesicle type are exosomes, which originate
from the endolysosomal compartment. Invagination of vesicles
into multivesicular bodies (MVBs) and their release after fusion
with the plasma membrane gives rise to exosomes with a
diameter between 30 and 120 nm (Thery et al., 2002). Due
to overlapping size ranges and limited specificity of current
enrichment and detection methods, in most cases MVs and
exosomes cannot be distinguished and both are referred to as
small EVs.
EV secretion has been shown for virtually any cell type. EVs
carry proteins, lipids and nucleic acids (Figure 1B) and thus are
critically involved in cell-to-cell communication. EVs participate
in autocrine, paracrine and systemic signaling processes and have
accordingly been detected in most body fluids. Mechanisms by
which EVs can elicit cellular responses are highly variable and
may depend on EV type, cargo, as well as their cellular origin.
Direct release of cargo into the extracellular space has been
described, as well as adhesion and/or uptake by target cells by
micropinocytosis or clathrin-mediated endocytosis in a receptor-
dependent or -independent manner (Cocucci and Meldolesi,
2015; McKelvey et al., 2015). After uptake, the vesicles might
enter the lysosomal pathway or fuse with endocytic membranes
resulting in the release of their cargo into the cytoplasm (Prada
and Meldolesi, 2016).
There is increasing evidence for a critical role of EVs
in progression of musculoskeletal diseases as well as tissue
regeneration. Here, we aim to summarize the role of EVs in
musculoskeletal tissues. Mesenchymal stromal cells (MSCs) have
been in the focus of therapeutic strategies for musculoskeletal
diseases for many years. Accordingly, next to potential
mechanisms and pathways targeted by EVs, we discuss MSCs as a
cell source of EVs and particularly address the parameters, which
might affect the phenotype of MSC-derived EVs (MSC-EVs). We
further provide practical considerations for developing EVs as
a cell-free, therapeutic tool and review examples of therapeutic
applications in musculoskeletal diseases.




Matrix Remodeling and Mineralization
EVs are generated by almost any cell type and can contain a
large variety of different cargoes. Databases like, e.g., Vesiclepedia
(http://microvesicles.org) and ExoCarta (http://www.exocarta.
org) provide regularly updated lists of proteins, lipids, and nucleic
acids that have been identified in EVs from different sources.
The exact composition of EVs derived from a specific cell type
depends on the microenvironment in the tissue that might
undergo changes during development or due to pathological
conditions (Cheng et al., 2017; Kusuma et al., 2017).
With regard to remodeling and mineralization, EVs can
contribute in several fundamentally different ways: (1) EVs
themselves transport remodeling or mineralization factors, or
carry the remodeling activities on their surface. (2) The activities
of EV membrane-associated proteinases and other enzymes
generate cleavage products or mobilize growth factors that
activate cells. (3) EVs stimulate cells via membrane receptors or
phagocytosis in an auto- or paracrine manner to release factors
that modulate remodeling and mineralization.
Several studies have indicated the presence of different
matrix metalloproteinases (MMPs) in and on EVs
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(Shimoda and Khokha, 2013, 2017). With regard to matrix
remodeling, MMP-2,−9,−13, and−14 could be of particular
importance as MMP-2 and−9 are gelatinases and all
aforementioned MMPs share collagenolytic activity. MMP-
14, also referred to as MT1-MMP, is a transmembrane protein
that acts as a sheddase by cleaving other transmembrane
molecules relevant in cell-cell and cell-matrix interactions, such
as the intercellular adhesion molecule 1 (ICAM-1, aka CD54),
the hyaluronan receptor (CD44), and the growth factor-binding
heparan-sulfate proteoglycan syndecan-1 (CD138) (Shimoda
and Khokha, 2017). MMPs are often activated in cascades, and a
recent study has shown that exosomal MMP-14 is able to cleave
and activate pro-MMP-2 (Hakulinen et al., 2008). Furthermore,
tissue inhibitor of metalloproteinases 3 (TIMP3)-sensitive
aggrecanase activity has been found in vesicles derived from
rheumatoid synovial fibroblasts, and it has been speculated
that this aggrecanase activity might play an important role in
remodeling aggrecan-rich matrices (Lo Cicero et al., 2012). The
activity of MMPs might not only degrade cell surface molecules
but also result in the release of bioactive cleavage fragments
that can further modulate remodeling processes (Karamanos
et al., 2019). In addition to proteases, glycosidases like sialidases,
and heparanases have been detected on the exosomal surface
(Sumida et al., 2015; Bandari et al., 2018; Sanderson et al.,
2019). These enzymes degrade a variety of glycosaminoglycans
and glycoproteins in the extracellular space where they might
not only contribute to matrix degradation but also to the
concomitant release of growth factors that are often bound to
glycan structures.
The crosslinking of collagens and elastin by lysyl oxidases
is a relevant process in stabilizing extracellular matrices (ECM)
in various musculoskeletal tissues. Indeed, a member of the
lysyl oxidase family, lysyl-oxidase-like 2 (LOXL2), has been
detected on EVs derived from endothelial cells. Interestingly,
under hypoxic conditions an increased enzymatic LOXL2
activity was detected (de Jong et al., 2016), demonstrating how
an altered microenvironment could affect matrix stability. In
rheumatoid arthritis (RA) and osteoarthritis (OA), not only
the decreased oxygen concentration but also pro-inflammatory
cytokines in the joint might similarly contribute to EV-mediated
remodeling processes (Fernandes et al., 2002; Ng et al., 2010;
Goldring and Otero, 2011). Treatment of chondrocytes with
interleukin-1β (IL-1β) in vitro, mimicking an inflammatory
OA environment, induces a release of EVs that stimulates
synovial fibroblasts to produce 3-fold higher levels of MMP-
13 in comparison to untreated control cells (Kato et al., 2014).
This observation confirms the role of EVs as messengers in
intercellular communication (Raposo and Stoorvogel, 2013).
In bone, all different cell types have been shown to be
involved in the remodeling process via EVs. In addition to
bone synthesis and resorption, EVs actively participate in the
regulation of ECM mineralization (Masaoutis and Theocharis,
2019). During endochondral ossification, EVs play an important
role in the initiation of the mineralization in the growth plate.
These vesicles were first described by Anderson (1967, 1969)
and Bonucci (1969) in the late 1960s and are still referred to
as matrix vesicles. Calcium, phosphate and phospholipids form
a nucleation core complex in the lumen of EVs derived from
chondrocytes and hydroxyapatite crystals start to grow. The
exact molecular mechanism of mineralization is still not known,
but eventually collagen fibrils in the ECM become mineralized
(Azoidis et al., 2018; Rilla et al., 2019). Since EVs can even
contribute to bone formation in adult rats (Hoshi and Ozawa,
2000), many investigations are currently focusing on therapeutic
applications using EVs in fracture repair (see section EV Therapy
in Fracture Healing).
Angiogenic Effects of EVs
Angiogenesis, defined as the formation of new vessels by
sprouting and ingrowth from the existing vascular network, is
critical for the regeneration of vascularized tissues, with bone
being one prominent example. Angiogenesis involves several
processes, including proliferation, recruitment, and migration of
endothelial cells as well as stabilization of newly formed vessels by
mural cells, such as pericytes. Effects of EVs have been described
for all of these steps. EVs with a role in angiogenesis may derive
from endothelial cells and their progenitors, platelets, various
immune cell populations, and MSCs. They have been reported
to exert pro- or antiangiogenic effects (Todorova et al., 2017)
that have been related to various signaling pathways, which
may be targeted by the corresponding ligands and cytokines
contained in EVs, such as: vascular endothelial growth factor
(VEGF) (Brill et al., 2005; Zou et al., 2016; Gangadaran et al.,
2017, 2020; Ahn et al., 2018; Tang et al., 2019), platelet-derived
growth factor (PDGF) (Brill et al., 2005; Ma et al., 2017) and
MMPs (Taraboletti et al., 2002; Han et al., 2019; Tang et al., 2019).
Moreover, a number of miRNAs involved in angiogenic effects
of EVs have been identified, e.g., pro-angiogenic miR31, miR-
125a, miR-126, miR-130a, miR-150, miR-210, miR214 (Li et al.,
2013; van Balkom et al., 2013; Kang et al., 2016; Liang et al., 2016;
Lombardo et al., 2016; Du et al., 2017a; Gong et al., 2017a; Wu
et al., 2018; Jia et al., 2019; Nie et al., 2019; Gangadaran et al.,
2020; Zhu et al., 2020).
Abundance of VEGF and subsequent targeting of the VEGF
receptor pathway is one of the mechanisms, which have been
accounted for the pro-angiogenic effects of EVs (Gangadaran
et al., 2017). Also, Notch pathway is well-known to be involved
in angiogenesis. Delta-like (Dll) 1, 3, and 4 and Jagged 1 and 2
are membrane bound ligands that bind to the Notch receptor
resulting in cleavage of its intracellular domain and subsequent
transcriptional changes (Luo et al., 2019). Different Notch-
ligands and regulators thereof have been identified in EVs and
associated with pro- (Liang et al., 2016; Gonzalez-King et al.,
2017) or anti-angiogenic effects (Tan et al., 2018). More signaling
pathways have been connected to the pro-angiogenic activity of
EVs, including Erk1/2 (Brill et al., 2005; Shabbir et al., 2015;
Lombardo et al., 2016; Zhang et al., 2016b; Wu et al., 2018; Jia
et al., 2019; Tang et al., 2019), PKA signaling (Xue et al., 2018),
PI3K/Akt signaling (Shabbir et al., 2015; Liu et al., 2017a; Ma
et al., 2017; Ji et al., 2019), Wnt4/βCatenin (Zhang et al., 2015a)
and NFκB (Anderson et al., 2016; Nie et al., 2019).
As also discussed in the section MSC as a Source of EVs—
Influence of “MSC State” on EVs, the microenvironment of
parental cells of EVs may have a significant impact on EV
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composition. This knowledge can be used to optimize EV-based
therapeutic approaches, for example, with respect to promoting
their angiogenic effects. Next to pro-angiogenic impact induced
by hypoxic preconditioning (Xue et al., 2018; Han et al., 2019;
Zhu et al., 2020), it has been demonstrated that nitric oxide
(NO) stimulation could augment the pro-angiogenic effects of
placenta-derived MSCs, which was attributed to increased levels
of miR-126 and VEGF (Du et al., 2017a). Similarly, PDGF
stimulation promotes the pro-angiogenic efficacy of adipose
tissue MSC-EVs (Lopatina et al., 2014).
Immunomodulatory Effects of EVs
EVs are important players in immune regulation and thereby
play a key role in musculoskeletal pathologies and regeneration.
Depending on the origin and state of the EV-releasing cell
(Robbins andMorelli, 2014; Burrello et al., 2016), they contribute
to both activation and suppression of immune responses. EVs,
especially originating from bone marrow MSCs (BMSCs), have
been heavily studied because of the immunomodulatory capacity
of MSCs and the hopes that MSC-EVs could be used as a potent
cell-free immune modulatory agent without facing the hurdles of
cell transplantation. Indeed, several in vitro and in vivo studies
could prove the immunosuppressive effects of EVs, and how they
interfere with innate, as well as adaptive, immune cells (Siegel
et al., 2009; Gomzikova et al., 2019). EVs can modulate the
functionality of T cells, B cells, dendritic cells (DC), macrophages,
natural killer cells (NK), and others (Burrello et al., 2016).
Interestingly, some of the therapeutic effects mediated by EVs
are comparable to their cell of origin (Fierabracci et al., 2015),
which suggests that EVs carry a similar molecular composition
and that the immune modulatory effect can be transferred
(Di Trapani et al., 2016). Recent research could show that
EVs contain tolerogenic molecules, such as programmed death-
ligand 1 (PD-L1), galectin-1, and transforming growth factor
(TGF)-β1 (Mokarizadeh et al., 2012). However, it should not be
concealed that EVs have been described to also activate immune
responses, for example, by transferring antigens and the major
histocompatibility complex (MHC) (Andre et al., 2004).
EVs modulate immune cell function in different ways: They
can inhibit the proliferation of CD4+ and CD8+ T cells and the
release of interferon (IFN)-γ and tumor necrosis factor (TNF)-α
(van den Akker et al., 2018). Furthermore, EVs can alter T helper
(Th) cell differentiation by fostering the differentiation of Th2 out
of Th1 cells and by inhibiting Th17 cell differentiation (Blazquez
et al., 2014; Chen et al., 2016; Ji et al., 2019). Lastly, EVs have been
shown to induce regulatory T cell generation, which can further
regulate ongoing immune responses (Zhang et al., 2014, 2018a; Ji
et al., 2019). This phenomenon is dependent on TGF-β and can
be blocked by neutralizing antibodies (Alvarez et al., 2018).
The extent of EV-mediated immune regulation seems to
be relative to the amount of received EVs: the more EVs are
incorporated by the acceptor cell, the more phenotypic changes
could be seen (Di Trapani et al., 2016). B cells have been
described to be an exceptionally good recipient for EVs. As
reaction to EV uptake, B cells showed reduced proliferation and
differentiation. Of further note, the proliferation of NK cells can
be reduced by EVs (Di Trapani et al., 2016), demonstrating their
immunomodulatory potential not only for adaptive immune
cells, but also in the innate immune system.
Recent investigations indicated that EVs affect the antigen
presenting cell (APC) properties of DCs. In addition to
compromising antigen uptake, they also diminished the
maturation of DCs, which subsequently resulted in a reduced
immune response. In line with this, EVs decreased the
production of pro-inflammatory cytokines and increased the
release of the anti-inflammatory cytokine TGF-β (Reis et al.,
2018). Similarly, EVs also modulate macrophage function by
inducing an anti-inflammatory M2-like phenotype (Henao
Agudelo et al., 2017). It has been shown that preconditioning
the EV-releasing cell can enhance the ability of EVs to influence
macrophage differentiation. Examples are hypoxia and LPS
challenge which increased the amount of MSC-EV-associated
miR-223 and miR-146b, as well as let-7b (Ti et al., 2015;
Lo Sicco et al., 2017), respectively, thereby leading to M2
polarization. Of note, these effects appear to be age-dependent
as discussed later (see section The Impact of Senescence and
Age-Related Changes). However, several other mechanisms have
been published describing how EVs can tweak macrophage
biology not only by involving single effector molecules, but
even mitochondrial delivery (Morrison et al., 2017). Although
MSC-EVs exert a variety of immune inhibitory properties, EVs
also stimulate the innate immune system, such as by inducing
M1 macrophage polarization during infection (Brauer et al.,
2020).
Because of their potential to negatively and positively interfere
with innate and adaptive immune responses, it is no surprise
that EVs, on the one hand, actively contribute to pathologies in
the musculoskeletal system and, on the other hand, are currently
under consideration to be exploited as therapeutic approaches in
regenerative medicine.
EVs have not only great therapeutic but also high prognostic
potential. Current research showed that knowledge about the
abundance and content of EVs could be used to improve
our understanding of several inflammatory diseases, especially
in situations where the immune system destroys tissue integrity,
such as in RA (Knijff-Dutmer et al., 2002; Skriner et al., 2006;
Rodriguez-Carrio et al., 2015; Maeda et al., 2017; Murphy et al.,
2018). Another example where EVs may serve as a biomarker,
are musculoskeletal infections. A recent study demonstrated that
synovial fluid of periprosthetic joints contains EVs, and that
they differ in number, size and composition in the presence
of an infection, as well as might influence the local immune
microenvironment (Ruwald et al., 2020).
In summary, EVs have a profound effect on a variety of
immune processes and thereby contribute to health and disease
in the musculoskeletal apparatus.
Senescence-Associated Vesicle Release
In response to stress signals, cells can restore their functions,
or undergo a cell death program to prevent persistence of
damaged and transformed cells (Takahashi et al., 2017; Gorgoulis
et al., 2019). On the other side, the cellular senescence program
enables survival of cells with permanent changes affecting their
microenvironment. Appearance of the senescence-associated
secretory phenotype (SASP) is followed by the activation of
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a distinct transcriptional landscape in comparison to primary
senescence (Kirschner et al., 2020) and secretion of high levels of
inflammatory cytokines, chemokines, and MMPs (Salama et al.,
2014) contributing to various age-related pathologies. Although
distinct cell lineages within the bone microenvironment
(osteoblasts, B cells, T cells) can dramatically increase SASP-
associated molecule production, particularly myeloid cells and
osteocytes of aged mice, contribute to age-related bone loss
(Farr et al., 2016), regulating osteoblast mineralization and
osteoclastogenesis (Farr et al., 2017).
In addition to the secretion of inflammatory molecules, the
release of EVs is also upregulated in senescent cells. A recent
study demonstrated that senescence-associated upregulation of
EV biogenesis, along with autophagy, can block apoptosis
and thus has a critical impact on cell homeostasis (Hitomi
et al., 2020). RNA-sequencing and liquid chromatography-mass
(LCM) spectrometry analysis revealed that several SASP proteins,
including TGF-β2, osteoprotegrin (OPG), MMP-9, TIMP1,
macrophage migration inhibitory factor (MIF)-1, peroxiredoxins
(PRDXs), and insulin-like growth factor binding protein (IGFBP)
3, were upregulated in EVs derived from aged mouse osteocytes
(Zhang et al., 2019; Aquino-Martinez et al., 2020). A proteomic
analysis of the senescence-associated secretome of fibroblasts
further revealed a significant abundance of plasma membrane
proteins in EVs (Basisty et al., 2020). Concomitantly, an increase
of all cargo miRNAs, which predominantly target mRNAs of
pro-apoptotic proteins, might be related to the anti-apoptotic
activity of senescent cell-derived EVs. In addition, senescence-
specific differences in miRNA composition of fibroblast EVs was
observed, where miRNAs were identified which were selectively
retained in senescent cells (miR-21-3p and miR-17-3p), or
packaged into senescent cell-derived EVs (miR-15b-5p and miR-
30a-3p) (Terlecki-Zaniewicz et al., 2018; Alibhai et al., 2020).
Aging can significantly alter the miRNA cargo of EVs in the
bone marrow microenvironment, which may, in turn, play a
role in stem cell senescence and osteogenic differentiation. Thus,
comparison of EVs derived from BMSCs isolated from young
(2–4 months) or aged (24–28 months) mice showed enrichment
of a miR-96/-182/-183 cluster in aged BMSC-EVs (Davis et al.,
2017). EVs derived from osteocytes isolated from 3 and 20
months old mice, revealed similar distribution of “exosomal
proteins,” including tetraspanins, flotillin, caveolin, integrins,
annexins, transcription factors (EF1A and EF2), heat shock
proteins and phosphatidylserine-binding protein, while “aged”
osteocyte-EVs lacked proteins involved in themaintenance of cell
homeostasis, regulation of cellular metabolism and osteoblast as
well as osteoclast differentiation. Furthermore, EVs from “aged”
osteocytes contained several factors, including CD44, CD47,
CD59, TGF-β2, and gelsolin, which regulate the activities of both
immune cells and bone cells, implying important communication
between “aged” osteocytes and immune cells (Zhang et al.,
2019).
Aged skeletal muscle is a potential source of circulating,
senescence-associated EVs expressing CD63 and TSG101
proteins that may impact on stem cell populations in bone via
miR-34a in vivo and ex vivo. It has been shown that senescent
muscle-derived EVs can induce cellular senescence in BMSCs,
revealing a potential mode of inter-organ crosstalk that may
affect bone physiology with aging (Fulzele et al., 2019). Together,
these findings suggest that EVs isolated from aged cells possess
certain specificities, and thus, consideration of donor age as
additional criteria for EVs’ isolation is desirable.
EVs in Bone Healing and Homeostasis
The native process of bone healing proceeds through overlapping
stages of inflammation, repair, and remodeling, which involve
multiple signaling pathways acting in concert within the bone
defect and the surrounding soft tissues (Oryan et al., 2017).
Immigrating MSCs into the bone defect secrete large amounts
of EVs and it was shown that EV-based approaches have the
potential to promote bone regeneration (see section EV Therapy
in Fracture Healing). These pleiotropic, mostly anabolic effects,
modulate metabolism and activity of all bone cell types during
osteogenic differentiation resulting in changes of bone turnover.
With respect to osteogenesis, the effects of MSC-EVs were
inhibited in the presence of LY294002 (phosphoinositide 3-
kinase inhibitor), implicating the involvement of PI3K/AKT
signaling in EV-induced osteogenesis (Zhang et al., 2016c). In
addition, mitogen-activated protein kinase (MAPK), BMP/Smad,
andWnt/β-catenin signaling pathways are involved in regulating
EV-induced osteogenesis (Tan et al., 2020). These effects may
be at least partly attributed to the protein cargo of MSC-EVs,
which accounts for more than 850 different proteins, including
TGF-β, insulin-like growth factor (IGF), PDGF and growth
differentiation factor (GDF) (Lai et al., 2012; Toh et al., 2017).
Numerous in vitro studies reported positive effects of MSC-
EVs on cell survival including anti-apoptotic effects (Tan et al.,
2020), proliferation and/or migration of a variety of cell types as
osteoblasts, macrophages, MSCs, and endothelial cells.
Important for exerting anabolic bone remodeling effects is
the role of EV cargo in the mutual communication of bone
cells, where the components of the EVs differ according to
the parental cell type. It was demonstrated that BMSC-derived
PKH67-labeled EVs were internalized by osteoblasts and got
distributed in diverse organelles promoting bone regeneration
(Qin et al., 2016). The other way round, EVs derived from
mineralized osteoblasts promote osteoblastic differentiation of
BMSCs by activating theWnt signaling pathway (Cui et al., 2016).
Osteocytes secrete EVs containing miRNAs that circulate in the
blood and may function as signaling molecules. Several miRNAs,
such as miR-29, miR-484, and miR-221, exist in EVs secreted
by mouse osteocyte-like cells (MLO-Y4 cells) (Sato et al., 2017).
EVs produced by osteocytic cells, which were preincubated with
myostatin could be taken up by osteoblastic MC3T3 cells. This
internalization led to a clear reduction of Runx2 expression, the
key regulator of osteoblastic differentiation, and subsequently,
to decreased osteoblastic differentiation via down-regulation of
the Wnt signaling pathway. Notably, the inhibitory effect of
myostatin-modified osteocytic EVs on osteoblast differentiation
was reversed by expression of exogenous miR-218 through a
mechanism involving miR-218-mediated inhibition of sclerostin
(SOST) gene expression (Qin et al., 2017). As discussed
before (see section Angiogenic Effects of EVs), EVs support
angiogenesis at different levels, these pro-angiogenic effects
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have likewise been proofed beneficial in the context of bone
regeneration (Xu et al., 2019a; Liu et al., 2020). In this line,
local ischemia is the main pathological incident in osteonecrosis
of the femoral head (ONFH). There is currently no effective
therapy to promote angiogenesis in the femoral head. When
iPS-MSC-exosomes were i.v. injected to a steroid-induced rat
osteonecrosis model they significantly prevented bone loss, and
increased microvessel density in the femoral head compared
with the control group (Liu et al., 2017a). Additionally, iPS-
MSC-EVs significantly enhanced the proliferation, migration
and tube-forming capacities of endothelial cells in vitro. The
authors conclude that the angiogenesis promoting effect might
be attributed to activation of the PI3K/Akt signaling pathway in
endothelial cells.
Taken together, MSC-EVs are carriers for biomolecules which
transfer messages to other cells in the bone microenvironment
and modulate bone homeostasis. These EVs exert potent effects
on cell survival, proliferation, and migration, to either promote
or delay bone regeneration.
EVs in Osteoporosis
Osteoporosis is a systemic multifactorial skeletal disorder that
results in fragile bones and an increased risk of fragility fractures
with minimal trauma. The pathogenesis is complex and includes
environmental and genetic factors. Osteoporotic fractures are
due to decreased bone mineral density (BMD) in combination
with deteriorated bonemicroarchitecture. Usually, BMD remains
stable until the age of about 55 years after which age-related
bone loss starts. Bone remodeling is a continuous physiological
process whereby old bone is removed by osteoclasts, and new
bone is formed by osteoblasts. This process is strictly regulated by
numerous signaling pathways (Almeida, 2012; Hendrickx et al.,
2015).
Several studies demonstrated that miRNAs released from
EVs may contribute to osteoporosis and age-related bone loss
indicating that it depends on the cell source whether EVs might
rather stimulate bone formation, or bone degradation. Notably,
EVs secreted by bone degrading cells, i.e., osteoclasts, are able
to suppress osteoblast activity by miRNAs. Elderly women with
fractures and ovariectomized mice (in vivo model for post-
menopausal bone loss) have elevated levels of EVs derived from
osteoclasts transportingmiR-214-3p (Li et al., 2016). Presumably,
inhibition of miR-214-3p can decrease bone loss during aging
and thus delay bone mass reduction resulting in osteoporosis.
MiR-183 increases in EVs of BMSCs after exposure to oxidative
stress (Davis et al., 2017). These “stressed” EVs can reduce
proliferation and osteogenic differentiation of young BMSCs
by targeting Hmox1 (gene encoding for heme oxygenase 1).
However, EV proteins are also involved in bone turnover and
can deregulate the delicate balance between bone degradation
and formation. For example, RANKL can be encapsulated
into EVs by human osteoblast cell lines. When treated
with parathyroid hormone, osteoblasts secrete more RANKL
containing EVs, which stimulate osteoclast differentiation (Deng
et al., 2015). In parallel, the number of RANK-containing
EVs increased in the late stage of osteoclast differentiation
and consequently inhibited osteoclast differentiation via RANK-
RANKL interactions (Huynh et al., 2016). These examples
demonstrate that crosstalk among bone cells is important for
bone homeostasis in both physiological and pathophysiological
conditions, and is –in part- regulated by EVs and their cargo.
Hence, EVs from pathologically altered cells in bone might
influence the outcome of treatments by counteracting effects
from “healthy” MSC-EVs.
In order to understand the underlying mechanisms of MSC-
EV effects, themolecular cargo of EVs was examined regarding its
potential to improve osteogenesis, cell survival, and angiogenesis
of bone cells and their precursors. It became evident that miRNAs
are critically involved in EV mediated effects. Kuang et al. (2019)
observed therapeutic efficacy of human umbilical cord (UC)
MSC-EVs in osteonecrosis and attributed the anti-apoptotic
and pro-survival effects of MSC-EVs to miR-21-mediated PTEN
(phosphatase and tensin homolog) downregulation and AKT
(protein kinase B) phosphorylation. Yang et al. (2020) reported
improved bone histological and structural parameters in a rat
model of disuse osteoporosis. This was attributed to increased
expression of yes-associated protein (YAP) and inhibition of the
Hippo signaling pathway. These effects of the UC-MSC-EVs were
partly recapitulated with miR-1263 mimics and abrogated with a
miR-1263 inhibitor.
Besides, EV cargo might function as independent diagnostic
and prognostic biomarker for bone metabolism. In particular,
this was observed for changes in serum concentrations of several
EV-miRNAs. The serum concentration of EV-derived miR-214-
3p, which prevents osteogenesis and bone formation, is increased
in elderly patients with fractures (Li et al., 2016). In osteoporotic
patients and elderly individuals, levels of miR-31 are also elevated
in serum. It is reported that EV-derived miR-31 is taken up
by MSCs and inhibits osteogenic differentiation by decreasing
the levels of frizzled-3 (Weilner et al., 2016). Furthermore, it
was shown that miR-21-5p serum level was reduced in post-
menopausal women with low bone mass (Yavropoulou et al.,
2017).
However, large scale prospective clinical studies are needed
to find out whether EV-derived miRNAs indeed can serve as
biomarkers for bone pathologies.
EVs in Trauma
In general, acute tissue trauma is characterized by inflammation,
cell death, and oxidative stress. Moreover, traumatic injuries lead
to early cellular senescence and activation of the innate immune
system, in particular the complement system, which potentiates
trauma effects (Huber-Lang et al., 2018; Jeon et al., 2019;
Riegger et al., 2020). While immunomodulatory and senescence-
associated effects of EVs have been discussed in the sections
before, the following will address cell death, oxidative stress and
complement activation.
Trauma-induced cell death compromises direct necrosis and
programmed cell death, such as apoptosis and necroptosis
(Zhao et al., 2015; Riegger and Brenner, 2019; Stolberg-Stolberg
et al., 2020). Apoptotic cells were found to secrete apoptotic
exosome-like vesicles (AEVs), expressing typical markers such
as CD63, lysosomal-associated membrane protein 1 (LAMP1)
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 6 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
and stress-associated heat shock proteins 70 (HSP70) (Park
et al., 2018). These AEVs loaded with “find me” and “eat
me” signals, attracting phagocytes and promoting phagocytotic
uptake (Caruso and Poon, 2018). Moreover, AEVs might act
as vehicles for damage associated molecular patterns (DAMPs)
(e.g., DNA and HMGB1), inducing inflammatory response
in macrophages (Caruso and Poon, 2018; Park et al., 2018).
Besides AEVs, various studies reported about EVs released
from necroptotic cells—also referred to as “necroptotic bodies”
(Zargarian et al., 2017). As these EVs predominantly carry the
executive effector protein of the necroptotic pathway, mixed
lineage kinase domain-like protein (MLKL), researchers suggest
that the EVs result from the shedding of MLKL-affected plasma
membranes, which might serve as a survival mechanism (Gong
et al., 2017b; Yoon et al., 2017). Comparable to AEVs, uptake
of these “necroptotic bodies” by macrophages or APCs results in
inflammatory signaling, chemotaxis, and antigen presentation to
T cells (Shlomovitz et al., 2020). Taken together, both apoptotic
and necroptotic cell-derived EVs might play an important role in
immunomodulation and clearance of dysfunctional or dying cells
(Zargarian et al., 2017; Caruso and Poon, 2018).
Concerning oxidative stress, EVs are thought to have
either direct or indirect effects differentially modulating
reactive oxidative species (ROS) metabolism, depending on
the physiological conditions (Bodega et al., 2019). In fact,
epithelial EVs derived from acute coronary syndrome patients
indirectly induced oxidative stress and premature endothelial
senescence in the recipient cells (Abbas et al., 2017). Moreover,
platelet-derived EVs from septic patients directly enhanced
cellular stress and subsequent apoptosis in endothelial and
vascular smooth muscle cells via NADPH oxidase (Janiszewski
et al., 2004). In contrast, direct antioxidative potential has been
reported for EVs loaded with various antioxidant enzymes,
like superoxide dismutase 2, catalase or glutathione peroxidase,
serving as ROS scavengers (Bodega et al., 2019). Indirect
antioxidative effects were described in case of MSC-EVs, which
alleviated harmful effects of acute kidney injury by enhancing
activation of nuclear factor E2-related factor 2 (Nrf2), the key
transcription factor of antioxidant responses (Zhang et al.,
2016a).
After trauma, there is also a local and systemic complement
activation as a major fluid phase innate immune system (Huber-
Lang et al., 2015; Chakraborty et al., 2018). Due to the
microenvironmental changes (e.g., ROS, DAMPs, proteases, and
coagulation factors), the complement cascade is rapidly activated
and generates anaphylatoxins, opsonins and membrane attack
complexes (MAC) (Ricklin et al., 2010; Chakraborty et al., 2018).
Concerning interactions of shedded vesicles with complement,
there is increasing evidence that these circulating vehicles contain
key complement factors, as well as complement regulators on
their surface, therebymodulating the pro- and anti-inflammatory
balance of the immune response and associated inflammation
(Karasu et al., 2018). Furthermore, the EVs themselves can
regulate complement activation, e.g., by harboring complement
receptor 1 (CR1), CD55, and CD59 (Karasu et al., 2018).
Overall, EVs may appear in a Janus-faced manner, on one
hand protecting cells from MAC-driven cell lyses by shedding
off the MAC from the cell surface, and on the other hand
increasing cellular susceptibility by shedding off CD59 as major
MAC inhibitor.
Taken together, EVs are involved in modulation of several
trauma-related pathomechanisms, promoting both harm-
reducing, but also detrimental effects; mainly depending on the
donor cell and physiological conditions.
EVs in Osteoarthritis (OA)
OA is a leading cause of disability and source of societal cost in
older adults. It is a whole-joint disease in which all components
of the joint are affected, involving structural alterations in the
articular cartilage with additional abnormalities in subchondral
bone, ligaments and synovium. During the development of
OA pathology, the composition, functional properties, and
structures of these tissues undergo marked alterations. Although
pathological processes might selectively target a single joint
tissue, ultimately all of the components are affected because of
their intimate association (Loeser et al., 2012). With an aging
and increasingly obese population in western countries, OA is
becoming even more prevalent than in previous decades. OA
accounted for 3.9% of years lived with disability worldwide in
2015, and by 2020 it is expected to be the fourth leading cause
of years lived with disability globally (Hunter et al., 2014).
EVs may critically contribute to disease progression in OA.
For example, it has been shown that EVs from IL-1ß-stimulated
synoviocytes, mimicking the inflammatory joint environment in
OA, displayed matrix remodeling activity as discussed before
(see sectionMatrix Remodeling andMineralization) and induced
proteoglycan release from cartilage explants. Inflammatory
cytokines, IL-6, MMP-3 and VEGF in EVs were only present at
a low level and IL-1ß, TNF-α, MMP-9, and MMP-13 were not
detectable in those EVs. In total, 50 miRNAs were differentially
expressed in EVs from IL-1ß stimulated synoviocytes compared
to non-stimulated cells (Kato et al., 2014)
As mentioned before EVs might also qualify as biomarkers.
A recent microarray analysis of miRNAs in EVs extracted
from synovial fluid showed that in samples from OA patients
miRNAs are differentially regulated in a gender specific
manner (Kolhe et al., 2017). The most differentially regulated
GO biological processes by up-regulated miRNAs in males
are cell-cell signaling, immune system process, response to
stress, and a number of TLR signaling pathways, whereas in
females cellular lipid metabolic processes, mitotic cell cycle
and clathrin-sculpted monoamine transport vesicle membrane
signaling is up-regulated. The most differentially regulated GO
biological processes by down-regulated miRNAs in females are
cell-cell signaling, immune system processes, innate immune
response and number of TLR signaling pathways, whereas in
males various metabolic processes (such as glycosaminoglycan,
chondroitin sulfate, phospholipid, and keratan sulfate), ECM
organization and cellular component assembly are reduced.
These observations might explain a prevalence of OA in females.
Based on the current knowledge of EVs from synovial fluid
(SF) and serum of patients with OA, at least three possible
diagnostic and prognostic EV biomarker types could be defined
for joint diseases. (1) Immune-cell-derived inflammatory EVs
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in the circulation could be a sign of early-onset joint disease;
(2) EVs in the SF of patients could provide information
about inflammation type, disease state and progression; (3) EVs
derived from synovial fibroblasts and chondrocytes, isolated from
healthy, non-OA affected individuals, could provide information
about predisposition for cartilage disorders (Malda et al., 2016).
MSC AS A SOURCE OF EVs—INFLUENCE
OF “MSC STATE” ON EVs
In the past years, many therapeutic approaches for
musculoskeletal disorders have been focused on MSC-based cell
therapies due to their differentiation and immunomodulatory
properties. MSC-EVs may account for a large part of these
functions and are therefore under investigation as an alternative
therapeutic approach to cell therapies. Application of EVs can
circumvent some drawbacks of cell-based therapies, as discussed
before (Toh et al., 2018). Successful clinical application of MSC-
EVs has already been described for the treatment of graft-versus
host disease (Kordelas et al., 2014).
MSC Source and Culture Conditions
It is well-established that MSC populations from different tissue
sources are not identical but exert tissue-specific characteristics
and functions (Sacchetti et al., 2016). Next to differences between
MSCs from different tissues and anatomical localizations,
isolation procedures and in vitro culture itself may also change
the phenotype of MSCs (Bara et al., 2014; Herrmann et al., 2016,
2019; Haddouti et al., 2020; Walter et al., 2020). Similarly, donor
characteristics such as age and sex, as well as co-morbidities
have been suggested to result in differences in MSC populations
(Muschler et al., 2001; Dexheimer et al., 2011; Cassidy et al.,
2020). Since it is generally assumed that the EV composition
mirrors the characteristics of the originating cell population,
aforementioned variabilities are likely to be transferred to the
resulting EV preparation. Indeed, it was demonstrated that
depending on the MSC source, the function and phenotype of
MSC-EVs vary profoundly (Borger et al., 2017). Using RNA
sequencing and comparative analysis, it has been shown that
EVs derived from MSCs of human adipose tissue (AT) vs.
bone marrow present a significantly different composition of
their content. These reports suggest that intrinsic differences
amongMSC-EVs isolated from different tissue sources need to be
considered as these differences may have a profound impact on
EV-activity and therapeutic outcomes (Mianehsaz et al., 2019).
These findings clearly indicate that MSC-EV-based therapies
need to be adapted and optimized for the intended therapeutic
application. Besides microenvironmental influences on theMSCs
(see section Influence of Pathophysiologic Environments on
MSC-EVs), further considerations are the choice of an allogenic
or autologous setting as well as scalability of the production
procedure when large EV quantities have to be produced, which
has been recently discussed by Adlerz et al. (2020).
Moreover, several parameters of the EV preparation
procedure have been reported to impact on EV yield and
composition (Witwer et al., 2019), which is of particular
importance for production of EVs for clinical application (see
also section Considerations for Clinical-Grade MSC-EVs). It has
been shown that cell seeding density may determine EV yield,
with lower seeding densities favoring higher EV production
rates. This study further suggested that shorter media collection
periods might further enhance EV yields, while MSC passage
did not account for significant differences (Patel et al., 2017).
EV yields might be of critical importance, especially when it
comes to therapeutic application. Thus, it should be noted that
dynamic cultivation methods and/or bioreactor systems have
been suggested to improve EV yields in different cell types (Yan
et al., 2018).
Composition of cell culture media is a major determinant
for the resulting EV preparation. In particular, fetal bovine
serum (FBS), commonly used as nutrient source in MSC cultures
contains high numbers of EVs itself, which unavoidably will
contaminate the EV preparation. Human platelet lysate (hPL)
is a well-established autologous alternative to FBS (Lang et al.,
2018), yet it might lead to proteomic changes in MSCs which
will most likely also be transmitted to EVs collected from these
cells (Loibl et al., 2016; Lang et al., 2017). Nevertheless, hPL
supplementation has been successfully used for EV production,
even for clinical application (Kordelas et al., 2014). Various
strategies have been established to avoid co-precipitation of
EVs from culture supplements as discussed below (see section
Isolation and Enrichment Protocols).
Thus, standardization of the isolation, characterization, and
expansion of MSCs is of utmost importance in the production of
EVs (Thery et al., 2018; Witwer et al., 2019).
Influence of Pathophysiologic
Environments on MSC-EVs
The Impact of Senescence and Age-Related Changes
Chronic inflammation in the elderly is described as a main
contributor to reduced regenerative capacity of the skeleton.
Inflamm-aging is induced by a pro-inflammatory cytokine
milieu, which can result from oncogenesis or BMSC driven
skewing of hematopoiesis toward the myeloid lineage, and these
effects are to a certain extent mediated by MSC-EVs (Lee and Yu,
2020).
Recent studies in mice demonstrated a critical influence of
inflamm-aging on skeletal stem cells and it can be assumed
that similar effects may occur in human MSCs, and eventually
also affect MSC-EVs. In this context, it was shown that skeletal
stem/progenitor cells (SSPCs) from young mice (3 months)
exposed to sera from middle-aged mice (13 months) developed
a reversible age-associated cytokine profile, subsequently leading
to a systemic pro-inflammatory environment. This study pointed
out the possibility to restore SSPC potential by abrogating
their senescent profile using rejuvenating anti-inflammatory
treatments (Josephson et al., 2019). In addition, BMSC-EVs
might have significant age-dependent differences in their
immune activities. Namely, BMSC-EVs from the adult group
contained the highest level of miR-335, associated with cell
senescence and, while “younger” BMSC-EVs contained the
highest level of miR-21, involved in negative regulation of
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macrophage-induced inflammation (Fafian-Labora et al., 2017).
Although, “young” and “aged” human AT-MSC-EVs shared
similar phenotype features, only “young” MSC-EVs showed
protective roles in LPS-induced lung injury in a mouse model
where these EVs induced M2 polarization in macrophages and
reduced macrophage recruitment. This was associated with
higher expression of miR-223-5p and lower levels of miR-
127-3p and miR-125b-5p in “young” MSC-EVs (Huang et al.,
2019). EVs isolated from early-passage human MSCs (about
15 population doublings, PD15) and late-passage MSCs (PD40)
differently regulated immune cell activity. PD15 MSC-EVs were
more effective than PD40 EVs in suppressing the secretion of
Th1 and Th17 cytokines, as well as IFN-γ, in stimulated mouse
splenocytes, while the effects of their EVs on the secretion of
TNF-α and IL-6 in stimulated splenocytes were similar. Upon
administration in LPS-challenged mice, only early-passage MSC-
EVs showed immunosuppressive potential, where proteomic
data revealed that early-passage MSC-EVs are enriched in TGF-
βI, PTX3, EDIL, BGN, and LUM proteins (Kim et al., 2020).
Emerging evidence indicates EVs as important mediators of
SASP effects, capable of transmitting paracrine senescence to
nearby cells by regulating cell proliferation, and inflammation
(Takasugi, 2018; Borghesan et al., 2020). It was shown that
when “young” murine BMSCs endocytosed EVs derived from
aged marrow, this led to reduction of osteogenic differentiation
and proliferation in “young” MSCs, increasing their senescence
(Davis et al., 2017). On the other side, purified induced
pluripotent stem cell (iPSC)-EVs added to senescent MSCs
showing high level of ROS production could reduce cellular
ROS levels and alleviated aging phenotypes of senescent MSCs.
This effect was mediated by delivery of intracellular antioxidant
enzymes, PRDX1 and PRDX2 (Liu et al., 2019). Although certain
potential of EVs from young individuals to attenuate senescence-
related cell damage was observed, additional experiments are
needed to completely reveal the rejuvenating potential of MSC-
EVs (Melidoni, 2020).
Collectively, understanding of senescence program
heterogeneity, together with permanent interaction with
immunity, might improve current approaches for targeting
senescent cells by senolytics, senostatics, or senogenics.
Elucidation of EV contents and mechanisms of paracrine
senescence would be of interest to set up optimal diagnostic and
therapeutic strategies (Jeon et al., 2019; Kirschner et al., 2020).
Particularly, improved characterization of aged cell-derived EVs
would allow a better prediction of EV-derived effects achieved
in healthy (incidental) and diseased (targeted) habitats. Also,
conduction of in vivo and human cell-based studies in the future
will reveal the translational relevance.
The Impact of a Diseased Environment
In addition to inflammation and age-related changes in MSC
discussed before, it has also been suggested that their phenotype
is affected by specific disease environments, such as osteoporosis,
or OA (Egermann et al., 2010; Benisch et al., 2012; Camernik
et al., 2020). Based on the evidence that the protein cargo of
EVs reflects the pathophysiological status of the parental cells
(Mianehsaz et al., 2019), it can be assumed that these traits are
transferred to the derived EVs, and this has to be considered
when choosing the MSC source for EV production.
Not much has been reported yet about the influence of a
pathophysiological osteoporotic or OA microenvironment on
the cargo of EVs. Nevertheless, analysis of cargos of EVs prepared
from RA and OA patients clearly revealed differential expression
of mRNAs, miRNAs, transcription factors, signaling molecules,
and other proteins, according to disease entity. The cargo of
EVs isolated from SF is different between OA patients and those
without OA (Withrow et al., 2016). The content of the OA EVs
revealed a several-fold increase in miR-200c, which is oxidative
stress-sensitive and indirectly represses transcription factor ZEB1
that plays a role in maintaining articular cartilage homeostasis.
Collectively, these data demonstrate that not only the
cellular origin of EVs needs to be considered, but also
a potential pathophysiological vs. physiological state of the
corresponding tissue.
Alternative Cell Sources
iMP-EVs as an Alternative to MSC-EVs
The transcriptional and metabolic programs that define a “cell
state” acquired during cell differentiation, tissue development,
pathology, and age, are set by epigenetic modifications of
the chromatin. Epigenetic reprogramming can revert these
modifications along with the acquired “cell state” and rejuvenate
cells to regain the cellular phenotype in the very early embryo
(Takahashi and Yamanaka, 2006; Takahashi et al., 2007). Thus,
the resulting reprogrammed iPSCs restore their unlimited
proliferative potential and the capacity to differentiate into
virtually any cell type (Tabar and Studer, 2014), including MSC-
like mesenchymal progenitor cells (iMPs). Therefore, iPSCs-
derived iMPs offer an opportunity to obtain large amounts
of highly regenerative patient-specific EV-producing MSCs,
independently of donor age, tissue source, or disease.
Different approaches for differentiation of iPSCs into iMPs
have been reported frequently, including their subsequent
downstream specification into mesoderm-derived lineages, such
as chondrocytes, osteoblasts, and myocytes (Li et al., 2010; Guzzo
et al., 2013; Koyama et al., 2013; Diederichs and Tuan, 2014;
Frobel et al., 2014; Hynes et al., 2014; Kang et al., 2015). IMPs
comply with the defining characteristics of in vitro-cultured
MSCs (Dominici et al., 2006), as they express similar cell-
surface markers: CD90, CD73, CD105, and CD44, but not CD45
and HLA-DR. Similarly to MSCs, they are capable of in vitro
differentiation into osteogenic, chondrogenic, and adipogenic
lineages (Lian et al., 2010; Hynes et al., 2014). One very interesting
distinction from adult MSCs is that iMPs appear to maintain
an increased juvenility, as they resemble rather fetal MSC than
adult MSC characteristics according to RNA sequencing (Chan
et al., 2018), gene expression (Buchert et al., 2019; Spitzhorn
et al., 2019) and epigenetic data (Frobel et al., 2014). Whether
this juvenility is also transmitted by the produced EVs and
whether iMP-EVs can thus rejuvenate target cells and/or alleviate
senescence would be interesting to investigate.
Surprisingly, iMP-derived EVs have not been investigated
in full so far, with fewer than 15 studies reported to date
(Hu et al., 2015a; Zhang et al., 2015b, 2016d; Nong et al.,
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2016; Qi et al., 2016; Du et al., 2017b; Liu et al., 2017a; Zhu
et al., 2017; Kim et al., 2018; Fang et al., 2020). Therein,
iMP-EVs attenuated limb ischemia in a mouse model, where
treatment with iMP-EVs strongly reduced the incidence of
limb loss and increased microvessel density (Hu et al., 2015a).
Supportive mechanistic in vitro studies indicated that iMP-
EVs could stimulate migration, proliferation, and angiogenesis-
related gene expression of endothelial cells. Two subsequent
studies from the same group have reported that bone repair
could also be stimulated by iMP-EVs in a rat cranial head
model, as well as iMP-EVs could enhance mineralization and
ALP activity of MSCs cultured in osteogenic medium (Qi
et al., 2016; Zhang et al., 2016d). Moreover, steroid-induced
osteonecrosis in femoral heads of rats, as well as collagenase-
induced osteoarthritis in mice, were reduced by iMP-EVs (Liu
et al., 2017a; Zhu et al., 2017). While collectively these reports
appear to be promising concerning the therapeutic effectivity
of iMP-EVs for treatment of musculoskeletal disorders, an
independent reproduction of these studies, as well as detailed
elucidation of the mechanisms regulated by iMP-EVs, are
urgently needed as the next step. Fundamental mechanistic and
functional studies are required to identify the cargo of iMP-
EVs and the key molecules responsible for their mode of action
in specific in vivo settings. This will be essential for answering
the questions whether iMP-EVs can elicit similar regenerative
effects as transplanted MSCs, or can outperform MSC-EVs and
therefore offer iMPs as an attractive alternative cell source of EV
production for cell-free therapy. Identifying the therapeutically
active EV components will also facilitate future experiments
to modulate culture conditions and tailor iMPs to produce
EVs with a specific cargo composition. For example, molecules
supporting cartilage matrix production and suppressing matrix-
degrading enzymes, as well as pro-inflammatory cytokines would
be essential for cartilage regeneration, while stimulation of
angiogenic, immunomodulatory, and osteogenic activities would
be important for bone regeneration.
One hurdle yet to overcome is that iMPs are currently
strongly heterogenic and variable, which severely limits the
reproducibility of iMP studies (Diederichs and Tuan, 2014).
More sophisticated differentiation strategies that use temporally
varying cytokine cocktails to more stringently guide iPSC
differentiation into the mesodermal and then the mesenchymal
lineage have already brought first successes (Kreuser et al., 2020)
and will in future help overcome this limitation.
Taken together, iMPs are an inexhaustible and juvenile
alternative cell source for EV production that holds a promise to
overcome limited availability and activity of adult MSCs that are
compromised due to age and underlying pathologies of human
donors (Figure 2). While initial preclinical studies suggested
potent and broad therapeutic effects comprised by iMP-EVs,
follow-up detailed studies that would characterize high-quality
iMP populations and their EVs are required to establish whether
iMP-EVs could indeed fulfill these tremendous expectations.
Chondrogenic Stem/Progenitor Cells (CSPCs)
Some years ago, a small population of MSC-like progenitor
cells have been described within the cartilage—the chondrogenic
stem/progenitor cells (CSPCs) (Alsalameh et al., 2004; Fickert
et al., 2004; Koelling et al., 2009). Due to rather strong similarities
to BMSCs, it might be possible that CSPC-derived EVs represent
another interesting player or therapeutic tool in the pathogenic
scenario of OA. In fact, CSPCs are thought to be involved in
cartilage regeneration as implied by enhanced migratory activity,
proliferation and immunomodulatory features after cartilage
trauma (Seol et al., 2012; Riegger et al., 2018). Moreover, it
was recently shown that intraarticular application of EVs from
murine chondrogenic progenitor cells (CPC) attenuated OA
development in a murine destabilization of the medial meniscus
(DMM) OA model (Wang et al., 2020). Interestingly, CPC-EVs
from MRL/MpJ superhealer mice exhibited stronger therapeutic
effects as compared to CPC-EVs from non-superhealer mice,




Isolation and Enrichment Protocols
Many different EV isolation techniques have been developed
to date (Greening et al., 2015; Li et al., 2017; Monguio-
Tortajada et al., 2019). They are based on ultracentrifugation
(Momen-Heravi, 2017), ultrafiltration (Gupta and Marcela
Rodriguez, 2019), size-exclusion chromatography (Lobb and
Möller, 2017), immunoaffinity capture (Oksvold et al., 2015),
polymeric precipitation (Weng et al., 2016; Ludwig et al.,
2018), or microfluidic separation (Contreras-Naranjo et al., 2017)
(Figure 3). All these different approaches have been developed
to facilitate separation, purification, and concentration of EVs
from contaminating cell debris and interfering components of
cell culture media; as well as to enable purification of EVs from
different clinical sample matrices: primary blood (Wu et al.,
2017), urine (Street et al., 2017), amniotic fluid (Ebert and Rai,
2019), saliva (Lässer et al., 2012), etc. To facilitate isolation
of specific EVs, each protocol exploits a particular property
of EVs, such as their density, size, shape, or a specific set of
protein markers.
Methodological Approaches to Reduce
Contamination With Serum-Derived EVs and Serum
Albumin From EV-Conditioned Medium
Regardless of a protocol selected for EV preparation, measures
have to be taken to deplete the EV conditioned medium of serum
albumin that otherwise hinder EV preparation, purification,
and detection (Abramowicz et al., 2018; Lehrich et al., 2018).
Additionally, FBS supplementation of cell cultures can lead to
contamination of the EV preparation by serum-derived EVs,
which may also affect in vitro cell behavior, as it has been
shown for migration and proliferation (Shelke et al., 2014).
There are commercially available EV-depleted serum sources
(Kornilov et al., 2018), however, these are quite expensive.
Researchers often try to overcome this by preparing their own
EV-depleted serum. EV elimination protocols usually involve
prolonged ultracentrifugation (up to 18 h at 100 000 × g) of
diluted serum stocks (Shelke et al., 2014), or a preliminary
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FIGURE 2 | iMP as an alternative cell source of EVs. Although MSCs can easily be maintained in cell culture enabling the production of large volumes of
EV-conditioned medium, their proliferation and tri-lineage differentiation capacity declines during prolonged expansion and they are affected by donor variability.
Induced pluripotent stem cells (iPSC) that derive from a somatic cell that underwent reprogramming with Myc-Oct3/4-Sox2-Klf4-expressing lentivirus represent an
alternative cell source, with unlimited proliferation and differentiation potential that can overcome the donor variability issue. However, these benefits are surpassed by
the technical issues related to iPSC maintenance and expansion in culture, as they require expensive media supplements, meticulous day-to-day inspections and
handling, which make iPSC expansion in order to increase iPSC-EVs yield quite a challenging and expensive task. Alternatively, iPSC could be subjected to
transdifferentiation into mesenchymal progenitor cells (iMP). These cells possess combined characteristics of iPSCs and MSCs: on one hand, they could be easily
expanded and maintained in cell culture, like MSCs, and on the other hand, they inherit and retain the high proliferation and differentiation capacities of iPSCs.
ultrafiltration step of serum-containing media before it is usable
for cell culture (Kornilov et al., 2018). However, extended
ultracentrifugation can also lead to co-precipitation of serum
albumin and lipoproteins reducing the capacity of the resulting
media to support cell growth (Eitan et al., 2015). An alternative
to this would be an ultrafiltration approach that utilizes
commercially available filtrationmembranes with large pore sizes
of 500 or 1,000 kDa MWCO (molecular weight cut-off) (Gupta
and Marcela Rodriguez, 2019; He et al., 2019). These membranes
allow all serum proteins to pass freely through but capture
contaminating serum EVs. Such small volume size ultrafiltration
devices (up to 14ml load per device) are subjected to low-
speed centrifugation, thus all the nutrients and serum proteins
remain intact in the media, and cell growth is not affected
detrimentally. An even better solution could be the application of
the ultrafiltration approach without any centrifugation procedure
using stirred cell units that rely on air compression to pass
media through ultrafiltration membranes (Gupta and Marcela
Rodriguez, 2019). These are available in large volume sizes,
up to 400ml, thus allowing large volumes of EV-free media
preparations. Moreover, this approach could also be applied for
removing serum proteins that interfere with EV purification and
detection from EV-conditioned media before subjecting it to any
of the EV isolation protocols. Since serum protein sizes range
from∼ 67 (albumin, that comprises almost 50% of serum protein
content) to ∼ 900 kDa (IgM) (Issaq et al., 2007), ultrafiltration
of serum-containing medium through 500–1,000 kDa MWCO
membranes removes the interfering serum proteins from the
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FIGURE 3 | Overview of different methodological approaches for isolation and purification of EVs. MSC-EVs secreted into a cell culture supernatant are collected as
EV-conditioned medium (CM). All EV isolation protocols start with sequential low-speed centrifugation steps, to remove cell debris and large shed microvesicles. Next,
the cleared CM can undergo either ultracentrifugation (1), ultrafiltration (2), precipitation with PEG (3), immune-immobilization (4), or size-exclusion chromatography (5)
protocols resulting in isolated EV fractions. (1) CM is subjected to ultracentrifugation at 120 000 × g. For removing contaminating proteins, the EV pellet is additionally
dissolved in PBS, and the ultracentrifugation step is repeated. (2) In case of ultrafiltration, the CM is passed through a membrane with pore sizes over 500 kDa MWCO
by air pressure application. This results in concentrated CM with reduced serum protein and lipoprotein content. Next, the concentrated CM can either be subjected
to a next round of ultrafiltration, using a membrane with pores ≤ 100 kDa MWCO, to retain and capture EVs, or, alternatively, it can undergo the ultracentrifugation
procedure (1). For the PEG protocol (3), EVs are precipitated from the CM by 10% PEG in two rounds. The final EV pellet can be additionally purified with subsequent
ultracentrifugation steps. For the immunocapture protocol (4), CD9-, CD63-, or CD81-conjugated magnetic beads are incubated with CM, to capture EVs, which are
then immobilized by a magnet. After serial washing steps, the captured EVs are eluted from the beads. In case of size-exclusion chromatography (5), CM, or
concentrated CM, is loaded on a resin-filled column, and the CM content (EVs and medium proteins) is fractionated according to their size. This approach allows
isolation of uniformly-sized EV particles. All methods can be used as separate protocols or in various combinations, to fulfill different requirements for downstream
analyses and applications utilizing EVs.
conditioned medium, thus improves purity and detection of EVs
(Benedikter et al., 2017).
Methodological Approaches for Isolation of EVs: Pros
and Cons
For EV production, cells normally are grown in T flasks that
enable collection of culture media conditioned with secreted EVs.
However, this process has some limitations when a large input
volume, high yield and concentration are required for EV mass-
production. Additionally, the need to use FBS when cells are
cultured in a conventional system, brings more challenges when
EV manufacturing for clinical use requires homogeneous and
efficient EV preparations. These obstacles could be overcome
with application of bioreactors (Yan et al., 2018). Once the EV-
conditionedmedia has been produced and collected, it undergoes
different concentration, isolation and purification protocols. All
the protocols for EV isolation usually start with several initial
differential centrifugation steps, which are necessary to remove
dead cells, cell debris, and contaminating apoptotic bodies. After
this, the EV-conditioned media can undergo isolation protocols
utilizing an ultracentrifugation approach, or are subjected to
further concentration and serum albumin depletion steps, before
EV purification (Figure 3).
Ultracentrifugation-Based Protocols (1)
Ultracentrifugation is the classical approach for the isolation
of EVs (Momen-Heravi, 2017), in which the centrifugal force
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used typically ranges from ∼100 000 to 120 000 × g. The
formed pellet contains a crude EV preparation, and, for further
purification, the pellet is dissolved in PBS (phosphate-buffered
saline), and the ultracentrifugation step is repeated. There
are variations of the classical ultracentrifugation protocol. To
achieve a pure EV preparation, with particles of uniform size,
a sample can be layered onto the top of density gradient
medium (commonly, sucrose is used for the formation of step
gradients, and Percoll is applied to form continuous gradients)
and subjected to an extended round of ultracentrifugation
(Tauro et al., 2012; Momen-Heravi, 2017; Pérez-González et al.,
2017). The separated EVs can then be recovered by simple
fraction collection. A downside of a density gradient based
ultracentrifugation protocol is that its capacity is limited by the
narrow load zone. Additionally, fraction collection and recovery
might result in a substantial reduction of the EV yield. Although
the ultracentrifugation method is overall robust and has low
running costs in terms of necessary consumables and reagents, it
requires substantial investments in the initial equipment. Other
limitations of the protocol are a long running time, especially
when large volumes of conditioned media need to be processed,
and it is labor intensive. Moreover, high-speed centrifugation
may result in EV damage, and, if the density gradient step is
omitted, the EV preparation is often of low purity impeding
downstream analyses (Lamparski et al., 2002; Taylor and Shah,
2015).
Ultrafiltration-Based Protocols (2)
To reduce the time for processing large starting volumes of
EV-conditioned media, and to remove contaminating serum
proteins, and lipoproteins that might co-precipitate with the
EVs, additional measures could be taken. As mentioned above,
large volumes of starting media could be reduced using the
ultrafiltration devices that utilize membranes of pore sizes of
500 or 1,000 kDa MWCO. EVs’ size distribution between 50
and 150 nm would prevent them from passing through these
membranes, and excess of medium with all the contaminating
serum proteins is thus successfully removed (Gupta and Marcela
Rodriguez, 2019).
Polymer Precipitation-Based Protocols (3)
Another approach to isolate EVs is based on their precipitation
together with polymers, such as polyethylene glycol (PEG)
(Weng et al., 2016; Ludwig et al., 2018). PEG alters the
solubility of EVs as it extrudes water from the solution.
The aqueous PEG wraps EVs together, thereby forming EV
aggregates which can be then precipitated by a low-speed
centrifugation step. This method is very cost-effective, as it does
not require expensive equipment or reagents. It also can be
applied for the isolation of EVs from biological fluids, such as
whole blood, plasma, urine, etc. (Rider et al., 2016; Lv et al.,
2018). The downside of this protocol is that other non-EVs
contaminants, such as proteins and polymeric materials, could
co-precipitate, thus pre-and post-clean-ups are usually needed,
including ultracentrifugation and ultrafiltration steps that were
mentioned before.
Size Exclusion Chromatography-Based Protocols (4)
A popular size-based separation technique for EV isolation and
purification is size exclusion chromatography (SEC) (Lobb and
Möller, 2017). For this, a porous material to sort particles of a
defined size is used as an immobilized phase in a column, and
EV-containingmedium is passed through the column, to separate
all the macromolecules and particles according to their size. This
method results in structurally intact and size-unified EVs with
high purity and integrity, thus SEC is especially in demand for EV
applications for immunosuppressive effects (Monguio-Tortajada
et al., 2017, 2019). However, the downside of this approach
is a low sample capacity, high running costs, and it is time-
consuming. Additionally, this method is not suitable when the




This method used for EV isolation involves microbeads coated
with antibodies to certain protein markers present on the EV
surface (Oksvold et al., 2015; Poellmann et al., 2020). The
advantage of this technology is that it can isolate EVs from
any type of fluids. In this method, commercial magnetic beads
are mixed with the EV-containing sample, and, after short
incubation, the immobilized EVs are separated from the rest of
the medium by a magnet. After washing, EVs can be recovered
from the beads. For this, solutions containing SDS (sodium
dodecyl sulfate) or high salt concentrations, or glycine-based low
pH buffers can be used. However, depending on downstream
applications, neither of these elution buffers might be suitable, as
it can result in capture antibodies leaching, or EV loss due to their
incomplete recovery from the beads. Nevertheless, the advantage
of this isolation method is its ability to select a specific EV
population based onmarker expression regardless of EV size. But
with this comes the main limitation, as there is no universal EV
marker defined to date that is uniformly present in all EVs. It also
requires expensive reagents, as well as it has a low capacity and
yields that would be further decreased in a case when an antigenic
epitope is blocked or masked. Side-by-side comparison of several
commercially available kits for EV immunocapture demonstrated
that to achieve sufficient purity of the EV preparation, additional
washing and ultracentrifugation steps would be still required that
might also compromise its time and yield efficiency (Patel et al.,
2019).
In conclusion, despite of recent progress and advances
in the methodological approaches addressing EV isolation
and purification, no ideal universal method suitable for all
applications and tissue and cell types has been developed yet.
However, with many to date available approaches, there is
a strong fundament for researchers to adapt EV preparation
procedures to certain experimental needs.
Quality Control
EV preparations are subject of great heterogeneity due to
variability of the originating cells (see section MSC as a Source of
EVs—Influence of “MSC State” on EVs) and alterations arising
from different isolation strategies. However, for deciphering the
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functional relevance of EVs as well as the development of efficient
therapies with translational success, standardization is required.
Minimal criteria for definition and classification of EVs along
with recommendations for appropriate analyses have therefore
been published by the International Society for Extracellular
Vesicles (ISEV) in 2014 (Lotvall et al., 2014) and updated in 2018
(Thery et al., 2018). Most commonly applied measurements are
briefly summarized below.
EV Visualization
SEM (scanning electron microscope) and TEM (transmission
electron microscope) are recommended to characterize the
morphology and distribution of EVs (Wu et al., 2015). Using
SEM, EVs isolated from MSCs exhibit a round morphology
and uniform distribution in size. On the other hand, TEM
is considered as a standard tool for characterizing the
morphology of EVs. Observed by TEM, MSC-EVs show a typical
“cup-shape” morphology.
EV Size Distribution and Concentration
Light scattering technologies, for example, NTA (nanoparticle
tracking analysis) are frequently applied to determine the size
distribution and concentration of EVs, alternatively tunable
resistive pulse sensing (TRPS) can be used. Additionally,
standard flow cytometry and high resolution flow cytometry are
used for larger or smaller EVs, respectively (Atkin-Smith et al.,
2015; Maas et al., 2015).
EV Protein Marker
Flow cytometry and Western blot analyses are commonly used
to identify membrane protein markers of EVs. For example, the
transmembrane proteins (CD9, CD81, and CD63) and accessory
proteins (Alix, TSG101, HSP70, and HSP 90) are valuable as
biomarkers of EVs (Doyle and Wang, 2019). However, some
proteins, which are not constituents of EV structures, are usually
co-isolated with EVs in the procedure of ultracentrifugation.
Therefore, GM130, calnexin, apolipoproteins A1/2, and B
(APOA1/2, APOB), and albumin were reported as negative
protein markers for EV preparations to assess the purity of EVs
(Sódar et al., 2016; Karimi et al., 2018).
Considerations for Clinical-Grade
MSC-EVs
There is great interest and research effort in translatingMSC-EV-
based therapies into clinical application. Production of clinical
grade EVs however requires highest standards of standardization
and reproducibility, where variabilities on the level of parental
cells as wells as culture conditions have a critical impact as also
discussed above (see section MSC as a Source of EVs—Influence
of “MSC State” on EVs). These hurdles have been recently
recognized and addressed in a joint position paper bymembers of
the Society for Clinical Research and Translation of Extracellular
Vesicles Singapore (SOCRATES), the International Society for
Extracellular Vesicles (ISEV), the International Society for Cell
and Gene Therapy (ISCT) and the International Society of Blood
Transfusion (ISBT) (Witwer et al., 2019). The paper suggests to
build guidelines for MSC-EVs on both, the MISEV criteria for
EVs (see sections Quality Control, EV Visualization, EV Size
Distribution and Concentration, and EV Protein Marker) and
the definition of human MSCs established by the Mesenchymal
and Tissue Stem Cell Committee of the ISCT (Dominici et al.,
2006). In addition, it has been recommended to specify the
source of MSCs, the age and passage of MSCs and to conduct
functional testing of MSC-EVs to verify the capability of MSCs
in producing functional EVs. Because different protocols for
purification of EVs may lead to different results, including the
purity and yield, it is critical to define the standard isolation of
EVs as described above and it needs to be recognized that it is
likely that each MSC-EV preparation leads to a different product.
The challenges related to the clinical translation of MSC-EVs
have also extensively been discussed in a recent article (Maumus
et al., 2020).




Almost all musculoskeletal diseases have an immunogenic
component that could benefit from an immune modulatory
therapy, leading to a great interest of MSCs in musculoskeletal
research in the last couple of years. Therapies using MSC-EVs
could show promising results comparable to current treatment
regimens with MSCs but without the downsides that accompany
the usage of MSCs. Therefore, MSC-EVs could be a promising
single or adjuvant therapy for musculoskeletal diseases.
RA has been a particular focus in the context of EV research.
Current research suggests that EVs could be a novel avenue for
the immune therapeutic treatment of RA, an overview on in
vivo studies testing EV-based therapies for RA is presented in
Table 1. Casado et al. (2017) showed that EVs from BMSCs may
reduce antigen-specific T cell responses in an antigen-induced
synovitis RA model. In detail, associated leukocyte infiltration
and TNFα production were significantly reduced by injecting
MSC-EVs directly into the affected joint (Casado et al., 2017).
In line with these results, another in vivo study using murine
models of delayed-type hypersensitivity and collagen-induced
arthritis showed that EVs protected joint integrity by mediating
anti-inflammatory effects (Cosenza et al., 2018). Interestingly,
Skriner et al. (2006) showed that EVs from RA patients contained
citrullinated proteins. These proteins are known autoantigens
and biomarkers for RA and the fact that they can be found in
EVs underlines a potential role of EVs in the immune-relevant
distribution of citrullinated proteins. In line with this, another
study found that the amount of platelet-derived EVs might be
associated with RA activity (Knijff-Dutmer et al., 2002).
In the context of OA, the beneficial immunomodulatory
properties of MSC-EVs have been confirmed as well. In the
study of Tofino-Vian et al., EVs isolated from human AT-MSCs
exerted a protective effect on chondrocytes from OA patients
through multiple mechanisms, such as reducing the production
of inflammatory mediators (e.g., TNF-α, IL-6, PGE2, and NO),




























TABLE 1 | Summary of preclinical studies testing the therapeutic application of MSC-EVs in musculoskeletal disorders.
References Animal model Cell source, EV isolation Administration, dosage Follow-up Effects, underlying mechanisms
EV therapy in rheumatoid arthritis (RA)
Casado et al. (2017) Antigen (BSA)-induced
synovitis RA model (pig)
Porcine iliac crest BMSCs;
Ultrafiltration (UF)
Intra-articular (i.a.) injections of
MSC-EVs; 500 µg protein per
injection in 500 µL
7 days after i.a.
injections
Leukocyte infiltration and TNFα production were
significantly reduced







Fat pad injection for DTH, intra
venous (i.v.) for CIA; 250 ng
DTH: day 6; CIA:
until day 37
DTH: dose-dependent anti-inflammatory effect; CIA:
decreased clinical signs of inflammation, fewer
plasma blasts, and more Breg-like cells
Headland et al. (2015) K/BxN model of arthritis and
glucose-6-phosphate
isomerase (GPI)-induced
arthritis model (both mouse)
Human RA-derived synovial
fluid; human RA neutrophils
and macrophages; mouse
bone marrow; UZ
i.a. injection of MV (3 × 104 particles
in 5 µL PBS) at day 3 after arthritis
induction (K/BxN model); i.a. injection
of MV (3 × 104 particles in 5 µL PBS)





MV treatment prevented GAG loss in knees in both
exp. arthritis groups.
EV therapy in traumatic joint injuries and osteoarthritis (OA)
Cosenza et al. (2017) Collagenase-induced knee
OA (mouse)
Murine BMSCs; UZ i.a. injections at day 7 after
OA-induction. Injection of
MVs (500 ng/5 µL) or
Exos (250 ng/5 µL)
42 days after
OA-induction
• In MV/Exo groups: Protection of cartilage
(less degradation) and reduction in osteophyte
formation. Epiphyseal bone: higher BV/TV and
less degradation in MV/Exo groups.
• SB: as above and additional less calcification of
ligaments and menisci





i.a. injections at day 7, 14, and 21




WNT5A inhibition via miR-92a-3p; attenuated
progression of early OA/reduced cartilage damage
Zhu et al. (2017) Collagenase-induced knee
OA model (mouse)
Human iPSC-MSCs =
iMSCs (cell line CIP33),
synovial membrane-derived
MSCs (SMMSC); UF
i.a. injections at days 7, 14, and 21
post collagenase injection. 8 µL Exos




The OARSI scores in the iMSC-Exos, and
SMMSC-Exos groups were significantly lower than
in the OA group. ICRS scores revealed no significant
differences among the normal, iMSC-Exos, and
SMMSC-Exos groups but higher than the OA
group. Best results in the iMSC-Exos group.
Ni et al. (2019) Surgical destabilization of
the medial meniscus (DMM)
(mouse)
Human OA articular
chondrocytes; UZ and UF
i.a. injection of Exo-like vesicles
pre-treated with IL1ß (109 particles in
5 µL = ChCILpre) combined with
antagomiR (5 nM in 5 µL) biweekly for
4 weeks, starting 4 weeks
post-surgery
8 days post-surgery i.a. injection of ChCILpre Exos aggravated cartilage
erosion and synovitis in DMM induced OA mice,
while antagomiR-449a-5p could partially reverse
ChCILpre-Exo-mediated cartilage damage






i.a. injections, from the 5th to the 8th




Deceleration of OA progression (reduced joint wear
and ECM loss/no type I collagen expression);
miR-140-5p-mediated maintenance of SOX9 via
inhibition of the Ras-like GTPase RalA and
subsequent recovery of ECM secretion.
Wang et al. (2017) DMM (mouse) Human embryonic stem
cell-induced mesenchymal
stem cells (ESC-MSCs); UZ
i.a. injections of 5 µL (1 × 106) EVs




Lower OARSI score; increased expression of type II































































































TABLE 1 | Continued
References Animal model Cell source, EV isolation Administration, dosage Follow-up Effects, underlying mechanisms




i.a. injections of 6 µL (1 × 108)




Improved histological properties and lower OARSI
score; reduced protease activity and percentage of
MMP-13-positive chondrocytes; possibly mediated
through miR-199a, miR125b, miR-221, and
miR-92a
Chen et al. (2019) Osteochondral defect;
4mm diameter, 4mm depth
(rabbit)
Human BMSCs; UZ 3D printed ECM/GelMA/Exo scaffold;
200µg/mL
6 and 12 weeks
post-surgery
Enhanced M2 polarization of synovial macrophages,
reduced fibrocartilage formation, restored
chondrocyte mitochondrial function (mitoprotection)
Liu et al. (2017b) Osteochondral defect;




acellular tissue patch (o-nitrobenzyl
alcohol moieties modified hyaluronic
acids/gelatin); 1 × 1011 mL−1
12 weeks
post-surgery
Seamless integration with native cartilage matrix;
hyaline cartilage formation




Canine BMSCs; UZ i.a. injection of 100 µg MVs in 100 µL
PBS
6 weeks, 3 and 6
months
post-surgery
Increased healing of chondral defect over time,
more chondrocytes, more collagen formation,
increased defect filling






i.a. injections at day 0, 7, and 14
post-surgery; 200 µg Exos
suspended in 1mL 3% (w/v) HA
6 and 12 weeks
post-surgery
Improved biomechanical and structural properties
compared to HA-treated defects; hyaline cartilage
formation
Zhang et al. (2016d) Osteochondral defect;
1.5-mm diameter, 1-mm
depth (rat)
Human embryonic stem cell
line (hESCs; HuES9); TFF
i.a. injections of 100 µL (100 µg
Exos); directly post-surgery, then
weekly
6 and 12 weeks
post-surgery
Improved histological scores and complete
neotissue filling of defect (5 out of 6: hyaline
cartilage); reduced fibrous tissue formation
Zhang et al. (2018b) Osteochondral defect;





i.a. injections of 100 µL (100 µg
Exos); directly post-surgery, then
weekly
2, 6, and 12 weeks
post-surgery
Increased cellular proliferation/reduced apoptosis;
enhanced matrix synthesis (type II collagen);
regenerative immune phenotype (enhanced
M2/decreased M1 macrophages); lower IL-1ß and
TNF-α levels; overall improved repair of
osteochondral defects
EV therapy in fracture healing
Furuta et al. (2016) Femur fracture model of
male CD9-deficient mice
Human BMSCs and human
osteosarcoma cell line
(HOS); UZ
Local injection into the fracture part at
days 1 and 8 post fracturing; 100 µL
of concentrated Exos isolated from
2mL BMSC culture medium
0, 1, 2, 4, and 6
weeks post fracture
setting
BMSC Exos rescued delayed fracture healing in
CD9-deficient mice; Exos promoted fracture healing
(earlier bone union) in WT mice; HOS Exos had no
positive effects on fracture healing
Li et al. (2018) Skull defect model (4mm
critical sized hole) in male
BALB/C mice
Human adipose derived
stem cells (ASCs); UZ
Cylindrical PLGA scaffolds immersed
in 1 µg/µL Exos solution




Increased new bone formation along the border and
in the center of the defects; increased collagen
formation; increased engraftment of host MSCs




Human iPSC-MSCs; UZ ß-TCP scaffolds loaded with
100µg/mL or 200µg/mL Exos
2, 4, 6, 8 weeks
after implantation
Increased BMD and BV/TV; increased
neovascularization (increased vessel area and
number); increased percentage of new bone
formation area
Xie et al. (2017) Male nude mice,
subcutaneous bone
formation model
Rat BMSCs; UZ EV-modified decalcified bone matrix
(DBM)-scaffolds (coated with 20 µg
EVs plus MSCs alginate solution)
were implanted subcutaneously
1 and 2 months after
implantation
EV-modified DBM scaffolds enhanced bone
regeneration in the central region of the grafts. A
higher average numbers of CD31-positive vessels
indicate promotion of vascularization
BMSCs, bonemarrow-derivedmesenchymal stem cells; WT, wild type; iPSC, induced pluripotent stem cells; iMSCs, inducedMesenchymal StemCells; ESCs, Embryonic StemCells; ECM, extracellular matrix; PLGA, poly(lactic-co-glycolic
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decreasing total MMP activity, and enhancing the production of
the anti-inflammatory cytokine IL-10 (Tofino-Vian et al., 2018).
In summary, EVs have a profound effect on a variety of
immune processes and thereby contribute to health and disease
in the musculoskeletal apparatus. Although some EVs seem to
play an active part in the immune-mediated pathogenesis of
musculoskeletal diseases, in contrast, MSC-released EVs might
have promising immune therapeutic potential.
One important challenge for EV-mediated immune therapy
is the standardization of EV manufacturing. It is commonly
accepted that MSCs are a heterogeneous population and
that their phenotype differs significantly depending on tissue
source and isolation procedure (see section MSC Source
and Culture Conditions). Since EVs, at least partly, reflect
the immunological molecular composition of the host cells,
consistent standardization of the isolation, characterization and
expansion of MSCs is of utmost importance in the production
of EVs (Thery et al., 2018; Witwer et al., 2019). This aspect
will be of particular importance for the near future of EV
research as clinical studies will only have little chance of success
if reproducibility issues cannot be worked out.
Remaining questions for EV-mediated immune therapy
mostly concern the cellular and molecular mechanisms of action
and will be the major focus of ongoing research: how do MSC-
EVs modulate immune cells and which molecules are involved?
As a next step, spatial information about the immunemodulatory
dynamics of EV products will be needed. This will provide details
about the bioavailability as well as cell-specific efficacy of EVs and
how both parameters can be optimized to produce more tailored
therapeutic interventions with less side effects. Also, novel tools
are needed to precisely track EVs in vivo to analyze distribution,
half-life period and to better forecast effective dosing (Hu et al.,
2015b; Vallabhaneni et al., 2015). These details will help to better
predict, separate and direct the immune stimulatory vs. anti-
inflammatory effects of MSC-EVs, and potentially enable the
generation of advanced synthetic EVs for optimized performance
(Conlan et al., 2017).
EV Therapy in Traumatic Joint Injuries and
OA
Therapeutic application of MSC-EVs revealed overall positive
effects in various situations of musculoskeletal trauma, including
repair of osteochondral lesions (Zhang et al., 2016d); in vivo
studies investigating EV therapies in this context are summarized
in Table 1. EV therapy after joint trauma and concurrent
cartilage injury, the main risk factor for the development of
post-traumatic osteoarthritis (PTOA), is therefore of critical
importance to avoid pathogenesis of OA. Up to date, no therapies
have been able to halt or delay OA progression satisfactorily
or provided effective and long-lasting symptomatic relief.
Therapeutic approaches predominantly addressed symptoms
and tried to modify/improve structural features of affected joint
tissues. Currently, in end stage OA, joint replacement with an
artificial prosthesis is the most effective measure to improve pain
sensation and quality of life in patients. The development of novel
therapeutic approaches targeting the osteoarthritic degradative
and inflammatory processes in cartilage, synovium, or bone
preferentially at an early stage, requires a deep understanding
of the disease status of these joint tissues at the time of the
intervention (Grassel and Muschter, 2020).
It has been shown, that MSC-EVs could attenuate OA
by stimulation of chondrocyte migration and proliferation
(Zhu et al., 2017). In addition, MSC-EVs could protect
cartilage and bone from degradation during OA pathogenesis
by increasing the expression of chondrocyte markers like
collagen II and aggrecan, reducing catabolic markers such as
MMP-13 and ADAMTS5, decreasing inflammatory markers
(iNOS), protecting chondrocytes from apoptosis, and blocking
of macrophage activation (Cosenza et al., 2017). Another
important finding of this group was that pre-treatment of MSCs
with TGF-β3 can improve the effectiveness of both EVs and
microvesicles/microparticles (MPs). Although the differences
were relatively small in comparison to non TGF-β3 pre-treated
BMSCs, the gene expression pattern was significantly different
in the EVs derived from pre-activated BMSCs. Influencing
the composition of EV cargo through ex vivo pre-treatment
and/or pre-activation of MSCs with different factors (e.g.,
TGF-β, IGF, or FGF) constitute another interesting therapeutic
approach to maximize anti-OA potential of EVs. When rat
chondrocytes internalized MSC-EVs, this lead to an increase in
their proliferation and migration rate that was at least in part
mediated via rapid activation of AKT- and ERK signaling through
CD73-mediated adenosine signaling (Zhang et al., 2018b).
In accordance with general tissue trauma, traumatic joint
injuries induce various pathomechanisms such as oxidative
stress, catabolic expression, and synovial inflammation. The
inflammatory response is predominantly associated with the
acute phase after trauma, and generally attenuates with time,
even though some cytokines remain elevated for months or even
years (Lieberthal et al., 2015). Likewise, generation and release
of other detrimental mediators, comprising pro-inflammatory
DAMPs, catabolic proteinases, and ROS, may proceed over years
and contribute to chondrocyte death (apoptosis and necroptosis),
complement activation, and phenotypical alteration, including
senescence and hypertrophy (Jeon et al., 2019; Riegger and
Brenner, 2019, 2020; Riegger et al., 2020). Despite the complexity
of these processes, recent in vivo studies on different animal
models of PTOA—critical-size osteochondral defect models, as
well as the DMM model—provide the first promising evidence
for the therapeutic efficacy of MSC-EVs after traumatic joint
injuries (Zhang et al., 2016d, 2018b; Liu et al., 2017b; Chen et al.,
2019).
In an osteochondral defect model, combination of hyaluronic
acid (HA) and EVs significantly improved hyaline cartilage
matrix repair and resulted in mechanically and structurally
superior tissue (Wong et al., 2020). Even without HA
supplementation, EV treatment of osteochondral defects was
found to promote complete restoration of the cartilage and
subchondral bone, while preventing formation of fibrous repair
tissue (Zhang et al., 2016d). Improved cartilage healing might
result from enhanced chondrocyte proliferation and biosynthesis
of ECM components (aggrecan, type II collagen), induced by
enhanced infiltration of CD163+ regenerative M2 macrophages
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and subsequent suppression of pro-inflammatory synovial
cytokines, as described in a comparable model (Zhang et al.,
2018b). Furthermore, it has been observed that even delayed
EV administration could reverse DMM-induced post-traumatic
cartilage degeneration in mice (Wang et al., 2017; To et al.,
2020; Woo et al., 2020). In these studies, EVs derived from
human embryonic stem cell-induced MSCs [ESC-MSCs; (Wang
et al., 2017)] or small EVs from human adipose-derived stem
cells were applied 4 or 5 weeks post-surgery, respectively.
Comparable results were found in a combined injury model
in rats, including transection of the medial meniscus and the
anterior cruciate ligament (Tao et al., 2017). Here, Tao et al.
(2017) reported improved efficacy of EVs derived frommiR-140-
5p-overexpressing synovial MSCs (SMSC) in preventing PTOA
development. In contrast, EVs from non-transfected SMSC
suppressed the chondrogenic phenotype in vitro and exhibited
limited chondroprotective effect in vivo (Tao et al., 2017). In
fact, origin of the donor cells and subsequent EV composition
might represent a crucial aspect concerning EV-mediated harm
reduction and regeneration after traumatic injury.
Meanwhile, novel EV application techniques have been
evolved to improve the healing of osteochondral defects in
the context of tissue engineering. As EVs maybe cleared
rapidly from joint space, they have been used as therapeutic
substances encapsulated and embedded in drug-delivery systems
consisting of different matrices, which help to achieve sustained
effects. These biomaterials are photo-induced imine crosslinking
hydrogel glue, gelatin methacrylate/nanoclay hydrogel or solid
3D printed cartilage ECM/gelatine methacrylate (GelMA)
scaffolds (Liu et al., 2017b; Chen et al., 2019; Hu et al., 2020). Liu
et al. implanted an acellular tissue patch (EHG) consisting of a
hydrogel glue blended with human iPSC-MSC-EVs into a rabbit
articular cartilage defect. They observed that EHG retained the
EVs and positively influenced chondrocytes and BMSCs in vitro.
Furthermore, the EHG integrated with the native cartilage matrix
and promoted cell deposition at the cartilage defect sites, finally
resulting in the promotion of cartilage defect repair. Chen et al.
(2019) reported that scaffold-based delivery of EVs enhanced
M2 polarization of synovial macrophages, reduced fibrocartilage
formation, and effectively restored chondrocyte mitochondrial
dysfunction, implying mitoprotective effects (Chen et al., 2019).
Mitoprotection can be considered as specific antioxidative
potential and has been found to prevent intracellular stress,
apoptosis and catabolic processes after cartilage injury (Delco
et al., 2018; Bartell et al., 2020).
Overall, stem cell secretomes and EVs applied intra-articularly
for the treatment of cartilage pathology in knee OA had
pleiotropic and mostly positive effects. Pre-clinical in vivo studies
in rat, mouse and rabbit OA models resulted in positive effects
on the joints and supported the effectiveness of EV intra-
articular injections as a minimally invasive therapy. Several
miRNAs transported in EVs showed beneficial effects in in
vivo studies, i.e., miR-92-3p. Mao et al. (2018) investigated the
molecular mechanism of exosomal miR-92a-3p and WNT5A in
chondrogenesis and cartilage degeneration. They showed that
MSC-EV-derived miR-92a-3p inhibited cartilage degradation in
their OA mouse model. The authors suggest that miR-92a-3p
regulates cartilage development and homeostasis by directly
targeting WNT5A. Possibly, EV-derived miR-92a-3p may act as
a Wnt inhibitor and exhibits potential as a disease-modifying
osteoarthritis drug. Weekly intra-articular injections of EVs from
MSCs generated from human ESCs resulted in improved repair
of critical-sized osteochondral defects in the femoral groove
in immunocompetent rats (Zhang et al., 2018b). Repetitive
intra-articular injections of canine BMSC-derived MVs showed
promising results in a canine chondral defect model (Sabry
et al., 2018). The group reported hat administration of MVs was
effective for the functional and morphological recovery of the
injured articular cartilage by increased defect filling of the lesion.
Accordingly, Ni et al. (2019) demonstrated that intra-articular
injection of exosome-like vesicles derived from IL-1β-pretreated
primary OA chondrocytes aggravated DMM-induced cartilage
erosion and synovial inflammation via miR-449a-5p.
Biodistribution of EVs following intra-articular delivery is
not known. Intra-articular administration of neutrophil-derived
EVs in a mouse model of inflammatory arthritis showed anti-
inflammatory properties and prevented cartilage degradation.
Anabolic effects were exerted by penetrating the cartilage ECM to
deliver bioactive molecules to the chondrocytes (Headland et al.,
2015).
Taken together, intra-articular EV injection might be a
promising approach to prevent the development of PTOA and
to improve structural damage of joint tissues in chronic OA.
Moreover, EVsmight enable hyaline cartilage restoration without
fibrous tissue formation; thus, facilitating one of the most
challenging issues in cartilage regeneration. Considering the poor
intrinsic regenerative capacity of adult human articular cartilage,
it might be reasonable to apply EVs directly after a traumatic
incidence to achieve an early harm reduction and reduce the risk
of irreversible cartilage damage and structural tissue alteration.
EV Therapy in Fracture Healing
Bone regeneration after injury is a complex multiphase process
involving many coordinated mechanisms that remove damaged
bone and tissue in order to generate a fully integrated
structurally competent replacement bone tissue (Hadjidakis
and Androulakis, 2006; Raggatt and Partridge, 2010; Loi
et al., 2016). There are a number of comorbidities, which
affect bone homeostasis and often result in fracture-healing
complications, such as ischemia, impaired vascularization, and
osteoporosis (Haffner-Luntzer et al., 2019). Complications in
bone regeneration are still a major challenge in clinical routine,
and thus developing new effective treatments with stronger
osteogenic potential and lower incidence of complications is
required. Over the last few years, EVs have received significant
attention in the field of bone repair and regeneration (Petho
et al., 2018). Many pre-clinical studies have revealed the high
potential of EV cargo in bone regenerative medicine (see Table 1
for a summary). Furuta et al. (2016) addressed the evaluation of
the role of exosomes isolated from human BMSC-conditioned
medium in the healing process in a femur fracture model of
CD9–/– mice, a strain that is known to produce reduced levels
of exosomes. Delayed fracture healing in CD9–/– mice was
rescued by the injection of exosomes and was associated with
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FIGURE 4 | The role of EVs in musculoskeletal diseases—from pro-regenerative to detrimental effects. EVs are an important component of cell communication in
musculoskeletal tissues. They can be produced by tissue resident cells as well as by cells, which invade in the process of disease progression and healing. As the
parental cells, also EVs and their cargo are affected by microenvironmental changes. EVs can contribute to physiological and pathophysiological processes and thus
critically influence tissue homeostasis and regeneration.
abundant callus formation 2 weeks after fracture. Bone union
at 3 weeks after fracture was similar to wild-type mice. In
addition, the timing of bone union was significantly shorter in
WT mice treated with exosomes compared with the control
groups. Tan et al. (2020) published a systematic review of
relevant preclinical studies, which were conducted to evaluate
the therapeutic efficacy of MSC-EVs for bone regeneration. A
total of 23 studies were identified, including a total sample
size of 690 rats or mice and 38 rabbits. Generally, it was
reported that MSC-EVs were efficacious for bone regeneration
in all analyzed animal models of bone defects and diseases
and did not show adverse effects. In these studies, MSC-EVs
promoted new bone formation with supporting vascularization
and displaying improved morphological, biomechanical, and
histological outcomes, coupled with positive effects on cell
survival, proliferation, migration, osteogenesis, and angiogenesis.
Lately, MSC-EVs combined with various scaffold materials
have been shown to generate bone at ectopic sites in vivo (Xie
et al., 2017) and successfully promoted bone repair in rodent
calvarial bone defects (Qi et al., 2016; Qin et al., 2016; Li et al.,
2018). Biocompatible scaffolds should degrade at a slow rate and
thus facilitate the controlled release of the EVs. Simply loading
results in a burst release and will be presumably less efficient as
a pro-regenerative approach for bone healing. Qi et al. (2016)
reported for a calvarial defect model in osteoporotic rats, that
treatment with tricalcium phosphate scaffolds loaded with EVs
isolated from human iPSC-MSCs contributed to bone defect
repair through induction of angiogenesis and osteogenesis. Li
et al. (2018) reported that human AT-MSC-EVs immobilized
onto poly-lactic-co-glycolic acid scaffolds exhibited a slow release
profile in vitro and promoted bone regeneration in a mouse
calvarial defect model after 6 weeks in vivo (Li et al., 2018).
In conclusion, these studies demonstrate that MSC-EVs and
their cargo are therapeutically efficacious in bone regeneration
in preclinical animal models and might be considered as
next generation therapeutic tools for the treatment of bone
pathologies. However, so far only small animal models have been
used to study the effects of EVs on bone regeneration and diseases
and no large animal studies (i.e., sheep, horses or minipigs)
are published. Further studies in large animal models are thus
required to establish the safety and efficacy before tackling the
design of clinical trials.
DISCUSSION AND FUTURE PERSPECTIVE
EVs are involved in numerous physiological and
pathophysiological processes in musculoskeletal tissues. By
carrying lipids, proteins and nucleic acids and having the
capability to direct them to specific targets (ranging from the
extracellular space or the circulation to receptor-mediated
cellular uptake), they present an important part of cellular
communication within tissues and on a systemic level. It appears
that EVs play an important role in tissue homeostasis. Likewise,
EVs have been associated with various pathophysiological
mechanisms such as matrix degradation or pro-inflammatory
effects in musculoskeletal disorders (Figure 4) and as such,
have been proposed as biomarkers. On the other hand, EVs
contribute to tissue regeneration by mitogenic, angiogenic and
immune modulatory effects, which renders them as potential
therapeutics in regenerative medicine (an overview of studies
investigating EV-based therapies for musculoskeletal disorders is
provided in Table 1). In common for all those features of EVs is
that we still lack the full insight in underlying mechanisms and
functional active components. Also, it is not fully understood
how the parental cell produces EVs and incorporates the
potential therapeutic effective molecules into the EVs. A detailed
understanding of how the recipient cell internalizes EVs is
critical to increase therapeutic effects of EVs and to develop
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highly efficient EVs for drug delivery and even gene therapy. This
will be a requirement for the translation of EV-based procedures
to clinical application.
The biggest hurdle in EV research so far are inconsistent
preparation and characterization methods, which have been
addressed by the ISEV by suggesting specific experimental
guidelines (Lotvall et al., 2014; Thery et al., 2018). While
still not implemented in all studies, these guidelines will
help to clearly assign functional outcomes to EVs. Other
practical considerations have to be addressed, such as potential
contamination of EV preparations with particles contained in
FBS or platelet products, or guaranteeingmaintenance of viability
and functions of parental cells when cultured with depleted
serum preparations or even under serum-free conditions. Finally,
very little is currently known about the therapeutic efficient
dose of EVs, which will have to be determined separately for
various applications and might lead to challenges when the EV
production process has to be dramatically scaled-up.
Currently, mostly small animal models have been used to
study the effects of EVs on musculoskeletal diseases and no
large animal studies are published yet. Consequently, the next
step should be the involvement of large animal models to
establish the safety and efficacy of the different musculoskeletal
EV therapy approaches. Large animal studies as in sheep, horses
or minipigs are commonly the prerequisite for designing first
clinical trials evaluating the therapeutic benefits of EVs in human
musculoskeletal disorders.
Nevertheless, there is a big need for new therapeutic strategies
in musculoskeletal diseases as incidences are increasing with
an ever-growing aging population and cell-based therapies have
shown limited success so far. In this light, EV-based therapies,
which can circumvent many of the disadvantages related to
cell therapies have a tremendous potential. EV-based therapies
may also benefit from EV-engineering approaches that aim
at modulating either the cargo or the targeting of EVs in
order to improve their therapeutic efficiency. This includes
the use of EVs as drug delivery vehicle and particularly for
the delivery of small molecules or nucleic acids as reviewed
elsewhere (Ramasubramanian et al., 2019). Incorporation in
EVs can overcome also problems arising from low solubility
or bioavailability of molecules, as demonstrated for the anti-
inflammatory agent curcumin (Sun et al., 2010; Moballegh
Nasery et al., 2020). Moreover, it has been proposed that
pre-conditioning (e.g., by hypoxia or inflammatory factors) of
parental cells may be applied to modulate the EV cargo and in
turn their therapeutic success with regards of e.g., angiogenic or
immunomodulatory effects (Xue et al., 2018;Martin-Rufino et al.,
2019). Such strategies have a great potential for the development
of efficient therapies for musculoskeletal diseases but yet need
further research efforts into the underlying mechanisms as
discussed above.
AUTHOR CONTRIBUTIONS
All authors have contributed to writting and editing of the
manuscript and have approved the final version.
FUNDING
This review was funded by a grant assigned to SG, SD, SM, MH,
FS, FZ, RB, and MH-L from the German Society for Orthopedic
and Orthopedic Surgery (DGOOC). MH and DT were supported
by the Interdisciplinary Center for Clinical Research (IZKF)
at the University of Wuerzburg (Project D-361). JR was
supported by the European Social Fund and by the Ministry
of Science, Research and Arts Baden-Wuerttemberg. ZJ-L and
FZ were supported by the Deutsche Forschungsgemeinschaft
(DFG) in Research Units FOR2407 (JE642/4-2 to ZJ-L,
project number 277277765) and FOR2722 (ZA561/3-1 to
FZ, project number 407168728). Figures 2, 3 were created
with Biorender.com.
REFERENCES
Abbas, M., Jesel, L., Auger, C., Amoura, L., Messas, N., Manin, G., et al.
(2017). Endothelial microparticles from acute coronary syndrome
patients induce premature coronary artery endothelial cell aging and
thrombogenicity: role of the Ang II/AT1 receptor/NADPH oxidase-mediated
activation of MAPKs and PI3-kinase pathways. Circulation 135, 280–296.
doi: 10.1161/CIRCULATIONAHA.116.017513
Abramowicz, A., Marczak, L., Wojakowska, A., Zapotoczny, S., Whiteside, T. L.,
Widlak, P., et al. (2018). Harmonization of exosome isolation from culture
supernatants for optimized proteomics analysis. PLoS ONE 13:e0205496.
doi: 10.1371/journal.pone.0205496
Adlerz, K., Patel, D., Rowley, J., Ng, K., and Ahsan, T. (2020). Strategies for scalable
manufacturing and translation of MSC-derived extracellular vesicles. Stem Cell
Res. 48:101978. doi: 10.1016/j.scr.2020.101978
Ahn, S. Y., Park, W. S., Kim, Y. E., Sung, D. K., Sung, S. I., Ahn, J. Y., et al.
(2018). Vascular endothelial growth factor mediates the therapeutic efficacy
of mesenchymal stem cell-derived extracellular vesicles against neonatal
hyperoxic lung injury. Exp. Mol. Med. 50:26. doi: 10.1038/s12276-018-0055-8
Alibhai, F. J., Lim, F., Yeganeh, A., DiStefano, P. V., Binesh-Marvasti, T., Belfiore,
A., et al. (2020). Cellular senescence contributes to age-dependent changes
in circulating extracellular vesicle cargo and function. Aging Cell 19:e13103.
doi: 10.1111/acel.13103
Almeida, M. (2012). Aging mechanisms in bone. Bonekey Rep. 1:102.
doi: 10.1038/bonekey.2012.102
Alsalameh, S., Amin, R., Gemba, T., and Lotz, M. (2004). Identification of
mesenchymal progenitor cells in normal and osteoarthritic human articular
cartilage. Arthritis Rheum. 50, 1522–1532. doi: 10.1002/art.20269
Alvarez, V., Sanchez-Margallo, F. M., Macias-Garcia, B., Gomez-Serrano, M.,
Jorge, I., Vazquez, J., et al. (2018). The immunomodulatory activity of
extracellular vesicles derived from endometrial mesenchymal stem cells on
CD4+ T cells is partially mediated by TGFbeta. J. Tissue Eng. Regen. Med. 12,
2088–2098. doi: 10.1002/term.2743
Anderson, H. C. (1967). Electron microscopic studies of induced cartilage
development and calcification. J. Cell Biol. 35, 81–101. doi: 10.1083/jcb.35.1.81
Anderson, H. C. (1969). Vesicles associated with calcification in the matrix of
epiphyseal cartilage. J. Cell Biol. 41, 59–72. doi: 10.1083/jcb.41.1.59
Anderson, J. D., Johansson, H. J., Graham, C. S., Vesterlund, M., Pham,
M. T., Bramlett, C. S., et al. (2016). Comprehensive proteomic
analysis of mesenchymal stem cell exosomes reveals modulation of
angiogenesis via nuclear factor-kappaB signaling. Stem Cells 34, 601–613.
doi: 10.1002/stem.2298
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 20 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
Andre, F., Chaput, N., Schartz, N. E., Flament, C., Aubert, N., Bernard, J., et al.
(2004). Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-
derived exosomes transfer functional MHC class I/peptide complexes to dendritic
cells. J. Immunol. 172, 2126–2136. doi: 10.4049/jimmunol.172.4.2126
Aquino-Martinez, R., Rowsey, J. L., Fraser, D. G., Eckhardt, B. A., Khosla, S., Farr,
J. N., et al. (2020). LPS-induced premature osteocyte senescence: implications
in inflammatory alveolar bone loss and periodontal disease pathogenesis. Bone
132:115220. doi: 10.1016/j.bone.2019.115220
Atkin-Smith, G. K., Tixeira, R., Paone, S., Mathivanan, S., Collins, C., Liem, M.,
et al. (2015). A novel mechanism of generating extracellular vesicles during
apoptosis via a beads-on-a-string membrane structure. Nat. Commun. 6:7439.
doi: 10.1038/ncomms8439
Azoidis, I., Cox, S. C., and Davies, O. G. (2018). The role of extracellular vesicles
in biomineralisation: current perspective and application in regenerative
medicine. J. Tissue Eng. 9, 1–11. doi: 10.1177/2041731418810130
Bandari, S. K., Purushothaman, A., Ramani, V. C., Brinkley, G. J., Chandrashekar,
D. S., Varambally, S., et al. (2018). Chemotherapy induces secretion
of exosomes loaded with heparanase that degrades extracellular matrix
and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118.
doi: 10.1016/j.matbio.2017.09.001
Bara, J. J., Richards, R. G., Alini, M., and Stoddart, M. J. (2014). Concise review:
bone marrow-derived mesenchymal stem cells change phenotype following
in vitro culture: implications for basic research and the clinic. Stem Cells 32,
1713–1723. doi: 10.1002/stem.1649
Bartell, L. R., Fortier, L. A., Bonassar, L. J., Szeto, H. H., Cohen, I., and Delco, M. L.
(2020). Mitoprotective therapy prevents rapid, strain-dependent mitochondrial
dysfunction after articular cartilage injury. J. Orthopaedic Res. 38, 1257–1267.
doi: 10.1002/jor.24567
Basisty, N., Kale, A., Jeon, O. H., Kuehnemann, C., Payne, T., Rao, C., et al. (2020).
A proteomic atlas of senescence-associated secretomes for aging biomarker
development. PLoS Biol. 18:e3000599. doi: 10.1371/journal.pbio.3000599
Benedikter, B. J., Bouwman, F. G., Vajen, T., Heinzmann, A. C. A., Grauls,
G., Mariman, E. C., et al. (2017). Ultrafiltration combined with size
exclusion chromatography efficiently isolates extracellular vesicles from cell
culture media for compositional and functional studies. Sci. Rep. 7:15297.
doi: 10.1038/s41598-017-15717-7
Benisch, P., Schilling, T., Klein-Hitpass, L., Frey, S. P., Seefried, L., Raaijmakers, N.,
et al. (2012). The transcriptional profile of mesenchymal stem cell populations
in primary osteoporosis is distinct and shows overexpression of osteogenic
inhibitors. PLoS ONE 7:e45142. doi: 10.1371/journal.pone.0045142
Blazquez, R., Sanchez-Margallo, F. M., de la Rosa, O., Dalemans, W., Alvarez, V.,
Tarazona, R., et al. (2014). Immunomodulatory potential of human adipose
mesenchymal stem cells derived exosomes on in vitro stimulated T cells. Front.
Immunol. 5:556. doi: 10.3389/fimmu.2014.00556
Bodega, G., Alique, M., Puebla, L., Carracedo, J., and Ramirez, R. M. (2019).
Microvesicles: ROS scavengers and ROS producers. J. Extracell. Vesicles
8:1626654. doi: 10.1080/20013078.2019.1626654
Bonucci, E. (1969). Further investigation on the organic-inorganic relationships in
calcifying cartilage. Calcif. Tissue Res. 3, 38–54. doi: 10.1007/BF02058644
Borger, V., Bremer, M., Ferrer-Tur, R., Gockeln, L., Stambouli, O., Becic, A.,
et al. (2017). Mesenchymal stem/stromal cell-derived extracellular vesicles and
their potential as novel immunomodulatory therapeutic agents. Int. J. Mol. Sci.
18:1450. doi: 10.3390/ijms18071450
Borghesan, M., Hoogaars, W. M. H., Varela-Eirin, M., Talma, N., and Demaria,
M. (2020). A senescence-centric view of aging: implications for longevity and
disease. Trends Cell Biol. 30, 777–791. doi: 10.1016/j.tcb.2020.07.002
Brauer, V. S., Pessoni, A. M., Bitencourt, T. A., de Paula, R. G., de Oliveira
Rocha, L., Goldman, G. H., et al. (2020). Extracellular vesicles from
aspergillus flavus induce M1 polarization in vitro. Msphere 5, e00190–e00120.
doi: 10.1128/mSphere.00190-20
Brill, A., Dashevsky, O., Rivo, J., Gozal, Y., and Varon, D. (2005).
Platelet-derived microparticles induce angiogenesis and stimulate
post-ischemic revascularization. Cardiovasc. Res. 67, 30–38.
doi: 10.1016/j.cardiores.2005.04.007
Buchert, J., Diederichs, S., Kreuser, U., Merle, C., and Richter, W. (2019). The
role of extracellular matrix expression, ERK1/2 signaling and cell cohesiveness
for cartilage yield from iPSCs. Int. J. Mol. Sci. 20:4295. doi: 10.3390/ijms2017
4295
Burrello, J., Monticone, S., Gai, C., Gomez, Y., Kholia, S., and Camussi, G. (2016).
Stem cell-derived extracellular vesicles and immune-modulation. Front. Cell
Dev. Biol. 4:83. doi: 10.3389/fcell.2016.00083
Camernik, K., Mihelic, A., Mihalic, R., Haring, G., Herman, S., Marolt Presen,
D., et al. (2020). Comprehensive analysis of skeletal muscle- and bone-derived
mesenchymal stem/stromal cells in patients with osteoarthritis and femoral
neck fracture. Stem Cell Res. Ther. 11:146. doi: 10.1186/s13287-020-01657-z
Caruso, S., and Poon, I. K. H. (2018). Apoptotic cell-derived extracellular vesicles:
more than just debris. Front. Immunol. 9:1486. doi: 10.3389/fimmu.2018.01486
Casado, J. G., Blazquez, R., Vela, F. J., Alvarez, V., Tarazona, R., and
Sanchez-Margallo, F. M. (2017). Mesenchymal stem cell-derived exosomes:
immunomodulatory evaluation in an antigen-induced synovitis porcine model.
Front. Vet. Sci. 4:39. doi: 10.3389/fvets.2017.00039
Cassidy, F. C., Shortiss, C., Murphy, C. G., Kearns, S. R., Curtin, W., De Buitleir,
C., et al. (2020). Impact of type 2 diabetes mellitus on human bone marrow
stromal cell number and phenotypic characteristics. Int. J. Mol. Sci. 21:2476.
doi: 10.3390/ijms21072476
Chakraborty, S., Karasu, E., and Huber-Lang, M. (2018). Complement after
trauma: suturing innate and adaptive immunity. Front. Immunol. 9:2050.
doi: 10.3389/fimmu.2018.02050
Chan, C. K. F., Gulati, G. S., Sinha, R., Tompkins, J. V., Lopez, M., Carter, A. C.,
et al. (2018). Identification of the human skeletal stem cell. Cell 175, 43–56.e21.
doi: 10.1016/j.cell.2018.07.029
Chen, P., Zheng, L., Wang, Y., Tao, M., Xie, Z., Xia, C., et al. (2019).
Desktop-stereolithography 3D printing of a radially oriented extracellular
matrix/mesenchymal stem cell exosome bioink for osteochondral defect
regeneration. Theranostics 9, 2439–2459. doi: 10.7150/thno.31017
Chen, W., Huang, Y., Han, J., Yu, L., Li, Y., Lu, Z., et al. (2016).
Immunomodulatory effects of mesenchymal stromal cells-derived exosome.
Immunol. Res. 64, 831–840. doi: 10.1007/s12026-016-8798-6
Cheng, L., Zhang, K., Wu, S., Cui, M., and Xu, T. (2017). Focus on mesenchymal
stem cell-derived exosomes: opportunities and challenges in cell-free therapy.
Stem Cells Int. 2017:6305295. doi: 10.1155/2017/6305295
Cocucci, E., and Meldolesi, J. (2015). Ectosomes and exosomes: shedding
the confusion between extracellular vesicles. Trends Cell Biol. 25, 364–372.
doi: 10.1016/j.tcb.2015.01.004
Colombo, M., Raposo, G., and Thery, C. (2014). Biogenesis, secretion, and
intercellular interactions of exosomes and other extracellular vesicles. Annu.
Rev. Cell Dev. Biol. 30, 255–289. doi: 10.1146/annurev-cellbio-101512-122326
Conlan, R. S., Pisano, S., Oliveira, M. I., Ferrari, M., and Mendes Pinto, I.
(2017). Exosomes as reconfigurable therapeutic systems. Trends Mol. Med. 23,
636–650. doi: 10.1016/j.molmed.2017.05.003
Contreras-Naranjo, J. C., Wu, H. J., and Ugaz, V. M. (2017). Microfluidics
for exosome isolation and analysis: enabling liquid biopsy for personalized
medicine. Lab Chip 17, 3558–3577. doi: 10.1039/C7LC00592J
Cosenza, S., Ruiz, M., Toupet, K., Jorgensen, C., and Noel, D. (2017).
Mesenchymal stem cells derived exosomes and microparticles protect
cartilage and bone from degradation in osteoarthritis. Sci. Rep. 7:16214.
doi: 10.1038/s41598-017-15376-8
Cosenza, S., Toupet, K., Maumus, M., Luz-Crawford, P., Blanc-Brude, O.,
Jorgensen, C., et al. (2018). Mesenchymal stem cells-derived exosomes are
more immunosuppressive than microparticles in inflammatory arthritis.
Theranostics 8, 1399–1410. doi: 10.7150/thno.21072
Cui, Y., Luan, J., Li, H., Zhou, X., and Han, J. (2016). Exosomes derived
from mineralizing osteoblasts promote ST2 cell osteogenic differentiation
by alteration of microRNA expression. FEBS Lett. 590, 185–192.
doi: 10.1002/1873-3468.12024
Davis, C., Dukes, A., Drewry, M., Helwa, I., Johnson, M. H., Isales,
C. M., et al. (2017). MicroRNA-183-5p increases with age in bone-
derived extracellular vesicles, suppresses bone marrow stromal (Stem) cell
proliferation, and induces stem cell senescence. Tissue Eng. A 23, 1231–1240.
doi: 10.1089/ten.tea.2016.0525
de Jong, O. G., van Balkom, B. W., Gremmels, H., and Verhaar, M. C. (2016).
Exosomes from hypoxic endothelial cells have increased collagen crosslinking
activity through up-regulation of lysyl oxidase-like 2. J. Cell. Mol. Med. 20,
342–350. doi: 10.1111/jcmm.12730
Delco, M. L., Bonnevie, E. D., Szeto, H. S., Bonassar, L. J., and Fortier, L. A. (2018).
Mitoprotective therapy preserves chondrocyte viability and prevents cartilage
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 21 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
degeneration in an ex vivomodel of posttraumatic osteoarthritis. J. Orthopaedic
Res. 36, 2147–2156. doi: 10.1002/jor.23882
Deng, L., Wang, Y., Peng, Y., Wu, Y., Ding, Y., Jiang, Y., et al. (2015). Osteoblast-
derived microvesicles: a novel mechanism for communication between
osteoblasts and osteoclasts. Bone 79, 37–42. doi: 10.1016/j.bone.2015.05.022
Dexheimer, V., Mueller, S., Braatz, F., and Richter, W. (2011). Reduced reactivation
from dormancy but maintained lineage choice of human mesenchymal stem
cells with donor age. PLoS ONE 6:e22980. doi: 10.1371/journal.pone.0022980
Di Trapani, M., Bassi, G., Midolo, M., Gatti, A., Kamga, P. T., Cassaro, A.,
et al. (2016). Differential and transferable modulatory effects of mesenchymal
stromal cell-derived extracellular vesicles on T, B and NK cell functions. Sci.
Rep. 6:24120. doi: 10.1038/srep24120
Diederichs, S., and Tuan, R. S. (2014). Functional comparison of human-
induced pluripotent stem cell-derived mesenchymal cells and bone marrow-
derived mesenchymal stromal cells from the same donor. Stem Cells Dev. 23,
1594–1610. doi: 10.1089/scd.2013.0477
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F., Krause,
D., et al. (2006). Minimal criteria for defining multipotent mesenchymal
stromal cells. The international society for cellular therapy position statement.
Cytotherapy 8, 315–317. doi: 10.1080/14653240600855905
Doyle, L. M., and Wang, M. Z. (2019). Overview of extracellular vesicles, their
origin, composition, purpose, and methods for exosome isolation and analysis.
Cells 8:727. doi: 10.3390/cells8070727
Du, W., Zhang, K., Zhang, S., Wang, R., Nie, Y., Tao, H., et al. (2017a).
Enhanced proangiogenic potential of mesenchymal stem cell-derived exosomes
stimulated by a nitric oxide releasing polymer. Biomaterials 133, 70–81.
doi: 10.1016/j.biomaterials.2017.04.030
Du, Y., Li, D., Han, C., Wu, H., Xu, L., Zhang, M., et al. (2017b). Exosomes
from human-induced pluripotent stem cell-derived mesenchymal stromal cells
(hiPSC-MSCs) protect liver against hepatic ischemia/ reperfusion injury via
activating sphingosine kinase and sphingosine-1-phosphate signaling pathway.
Cell. Physiol. Biochem. 43, 611–625. doi: 10.1159/000480533
Ebert, B., and Rai, A. J. (2019). Isolation and characterization of amniotic fluid-
derived extracellular vesicles for biomarker discovery.Methods Mol. Biol. 1885,
287–294. doi: 10.1007/978-1-4939-8889-1_19
Egermann, M., Heil, P., Tami, A., Ito, K., Janicki, P., Von Rechenberg, B., et al.
(2010). Influence of defective bone marrow osteogenesis on fracture repair
in an experimental model of senile osteoporosis. J. Orthop. Res. 28, 798–804.
doi: 10.1002/jor.21041
Eitan, E., Zhang, S., Witwer, K. W., and Mattson, M. P. (2015). Extracellular
vesicle-depleted fetal bovine and human sera have reduced capacity to
support cell growth. J. Extracell. Vesicles 4, 26373–26373. doi: 10.3402/jev.v4.
26373
Fafian-Labora, J., Lesende-Rodriguez, I., Fernandez-Pernas, P., Sangiao-Alvarellos,
S., Monserrat, L., Arntz, O. J., et al. (2017). Effect of age on pro-inflammatory
miRNAs contained in mesenchymal stem cell-derived extracellular vesicles. Sci.
Rep. 7:43923. doi: 10.1038/srep46850
Fang, S. B., Zhang, H. Y., Wang, C., He, B. X., Liu, X. Q., Meng, X. C.,
et al. (2020). Small extracellular vesicles derived from human mesenchymal
stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway
inflammation through delivery of miR-146a-5p. J. Extracell. Vesicles 9:1723260.
doi: 10.1080/20013078.2020.1723260
Farr, J. N., Fraser, D. G., Wang, H., Jaehn, K., Ogrodnik, M. B., Weivoda, M. M.,
et al. (2016). Identification of senescent cells in the bone microenvironment. J.
Bone Miner. Res. 31, 1920–1929. doi: 10.1002/jbmr.2892
Farr, J. N., Xu, M., Weivoda, M. M., Monroe, D. G., Fraser, D. G., Onken, J. L., et al.
(2017). Targeting cellular senescence prevents age-related bone loss in mice.
Nat. Med. 23, 1072–1079. doi: 10.1038/nm.4385
Fernandes, J. C., Martel-Pelletier, J., and Pelletier, J. P. (2002). The role of cytokines
in osteoarthritis pathophysiology. Biorheology 39, 237–246.
Fickert, S., Fiedler, J., and Brenner, R. E. (2004). Identification of subpopulations
with characteristics ofmesenchymal progenitor cells from human osteoarthritic
cartilage using triple staining for cell surface markers. Arthritis Res. Ther. 6,
R422–R432. doi: 10.1186/ar1210
Fierabracci, A., Del Fattore, A., Luciano, R., Muraca, M., Teti, A.,
and Muraca, M. (2015). Recent advances in mesenchymal stem cell
immunomodulation: the role of microvesicles. Cell Transplant. 24, 133–149.
doi: 10.3727/096368913X675728
Frobel, J., Hemeda, H., Lenz, M., Abagnale, G., Joussen, S., Denecke,
B., et al. (2014). Epigenetic rejuvenation of mesenchymal stromal cells
derived from induced pluripotent stem cells. Stem Cell Rep. 3, 414–422.
doi: 10.1016/j.stemcr.2014.07.003
Fulzele, S., Mendhe, B., Khayrullin, A., Johnson,M., Kaiser, H., Liu, Y., et al. (2019).
Muscle-derived miR-34a increases with age in circulating extracellular vesicles
and induces senescence of bone marrow stem cells. Aging 11, 1791–1803.
doi: 10.18632/aging.101874
Furuta, T., Miyaki, S., Ishitobi, H., Ogura, T., Kato, Y., Kamei, N., et al. (2016).
Mesenchymal stem cell-derived exosomes promote fracture healing in a mouse
model. Stem Cells Transl. Med. 5, 1620–1630. doi: 10.5966/sctm.2015-0285
Gangadaran, P., Rajendran, R. L., Lee, H. W., Kalimuthu, S., Hong, C. M., Jeong, S.
Y., et al. (2017). Extracellular vesicles from mesenchymal stem cells activates
VEGF receptors and accelerates recovery of hindlimb ischemia. J. Control.
Release 264, 112–126. doi: 10.1016/j.jconrel.2017.08.022
Gangadaran, P., Rajendran, R. L., Oh, J. M., Hong, C. M., Jeong, S. Y., Lee,
S. W., et al. (2020). Extracellular vesicles derived from macrophage promote
angiogenesis in vitro and accelerate new vasculature formation in vivo. Exp.
Cell Res. 394:112146. doi: 10.1016/j.yexcr.2020.112146
Goldring, M. B., and Otero, M. (2011). Inflammation in osteoarthritis. Curr. Opin.
Rheumatol. 23, 471–478. doi: 10.1097/BOR.0b013e328349c2b1
Gomzikova, M. O., James, V., and Rizvanov, A. A. (2019). Therapeutic
application of mesenchymal stem cells derived extracellular vesicles for
immunomodulation. Front. Immunol. 10:2663. doi: 10.3389/fimmu.2019.02663
Gong, M., Yu, B., Wang, J., Wang, Y., Liu, M., Paul, C., et al. (2017a).
Mesenchymal stem cells release exosomes that transfer miRNAs to
endothelial cells and promote angiogenesis. Oncotarget 8, 45200–45212.
doi: 10.18632/oncotarget.16778
Gong, Y. N., Guy, C., Olauson, H., Becker, J. U., Yang, M., Fitzgerald, P., et al.
(2017b). ESCRT-III acts downstream of MLKL to regulate necroptotic cell
death and its consequences. Cell 169, 286–300. doi: 10.1016/j.cell.2017.03.020
Gonzalez-King, H., Garcia, N. A., Ontoria-Oviedo, I., Ciria, M., Montero, J. A.,
and Sepulveda, P. (2017). Hypoxia inducible factor-1alpha potentiates jagged 1-
mediated angiogenesis by mesenchymal stem cell-derived exosomes. Stem Cells
35, 1747–1759. doi: 10.1002/stem.2618
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C.,
et al. (2019). Cellular senescence: defining a path forward. Cell 179, 813–827.
doi: 10.1016/j.cell.2019.10.005
Grassel, S., and Muschter, D. (2020). Recent advances in the
treatment of osteoarthritis. F1000Res. 9:F1000 Faculty Rev-1325.
doi: 10.12688/f1000research.22115.1
Greening, D. W., Xu, R., Ji, H., Tauro, B. J., and Simpson, R. J. (2015). A protocol
for exosome isolation and characterization: evaluation of ultracentrifugation,
density-gradient separation, and immunoaffinity capture methods. Methods
Mol. Biol. 1295, 179–209. doi: 10.1007/978-1-4939-2550-6_15
Gupta, S., and Marcela Rodriguez, G. (2019). Isolation and characterization
of extracellular vesicles produced by iron-limited mycobacteria. J. Vis. Exp.
152:e60359. doi: 10.3791/60359
Guzzo, R. M., Gibson, J., Xu, R. H., Lee, F. Y., and Drissi, H. (2013).
Efficient differentiation of human iPSC-derived mesenchymal stem cells to
chondroprogenitor cells. J. Cell. Biochem. 114, 480–490. doi: 10.1002/jcb.24388
Haddouti, E. M., Randau, T. M., Hilgers, C., Masson, W., Walgenbach, K. J.,
Pflugmacher, R., et al. (2020). Characterization and comparison of human and
ovine mesenchymal stromal cells from three corresponding sources. Int. J. Mol.
Sci. 21:2310. doi: 10.3390/ijms21072310
Hadjidakis, D. J., and Androulakis, I. I. (2006). Bone remodeling. Ann. N. Y. Acad.
Sci. 1092, 385–396. doi: 10.1196/annals.1365.035
Haffner-Luntzer, M., Hankenson, K. D., Ignatius, A., Pfeifer, R., Khader, B. A.,
Hildebrand, F., et al. (2019). Review of animal models of comorbidities in
fracture-healing research. J. Orthop. Res. 37, 2491–2498. doi: 10.1002/jor.24454
Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., and Keski-Oja, J. (2008).
Secretion of active membrane type 1 matrix metalloproteinase (MMP-14)
into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105,
1211–1218. doi: 10.1002/jcb.21923
Han, K. Y., Chang, J. H., and Azar, D. T. (2019). MMP14-containing exosomes
cleave VEGFR1 and promote VEGFA-induced migration and proliferation
of vascular endothelial cells. Invest. Ophthalmol. Vis. Sci. 60, 2321–2329.
doi: 10.1167/iovs.18-26277
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 22 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
He, L., Zhu, D.,Wang, J., andWu, X. (2019). A highly efficient method for isolating
urinary exosomes. Int. J. Mol. Med. 43, 83–90. doi: 10.3892/ijmm.2018.3944
Headland, S. E., Jones, H. R., Norling, L. V., Kim, A., Souza, P. R., Corsiero,
E., et al. (2015). Neutrophil-derived microvesicles enter cartilage and
protect the joint in inflammatory arthritis. Sci. Transl. Med. 7:315ra190.
doi: 10.1126/scitranslmed.aac5608
Henao Agudelo, J. S., Braga, T. T., Amano, M. T., Cenedeze, M. A., Cavinato,
R. A., Peixoto-Santos, A. R., et al. (2017). Mesenchymal stromal cell-derived
microvesicles regulate an internal pro-inflammatory program in activated
macrophages. Front. Immunol. 8:881. doi: 10.3389/fimmu.2017.00881
Hendrickx, G., Boudin, E., and Van Hul, W. (2015). A look behind the scenes:
the risk and pathogenesis of primary osteoporosis. Nat. Rev. Rheumatol. 11,
462–474. doi: 10.1038/nrrheum.2015.48
Herrmann, M., Bara, J. J., Sprecher, C. M., Menzel, U., Jalowiec, J. M., Osinga, R.,
et al. (2016). Pericyte plasticity - comparative investigation of the angiogenic
and multilineage potential of pericytes from different human tissues. Eur. Cell.
Mater. 31, 236–249. doi: 10.22203/eCM.v031a16
Herrmann, M., Hildebrand, M., Menzel, U., Fahy, N., Alini, M., Lang, S., et al.
(2019). Phenotypic characterization of bone marrow mononuclear cells and
derived stromal cell populations from human iliac crest, vertebral body and
femoral head. Int. J. Mol. Sci. 20:3454. doi: 10.3390/ijms20143454
Hitomi, K., Okada, R., Loo, T. M., Miyata, K., Nakamura, A. J., and Takahashi,
A. (2020). DNA damage regulates senescence-associated extracellular vesicle
release via the ceramide pathway to prevent excessive inflammatory responses.
Int. J. Mol. Sci. 21:3720. doi: 10.3390/ijms21103720
Hoshi, K., and Ozawa, H. (2000). Matrix vesicle calcification in bones of adult rats.
Calcif. Tissue Int. 66, 430–434. doi: 10.1007/s002230010087
Hu, G. W., Li, Q., Niu, X., Hu, B., Liu, J., Zhou, S. M., et al. (2015a). Exosomes
secreted by human-induced pluripotent stem cell-derived mesenchymal stem
cells attenuate limb ischemia by promoting angiogenesis in mice. Stem Cell Res.
Ther. 6:10. doi: 10.1186/scrt546
Hu, H. X., Dong, L. L., Bu, Z. H., Shen, Y. F., Luo, J., Zhang, H.,
et al. (2020). miR-23a-3p-abundant small extracellular vesicles released from
Gelma/nanoclay hydrogel for cartilage regeneration. J. Extracell. Vesicles
9:1778883. doi: 10.1080/20013078.2020.1778883
Hu, L., Wickline, S. A., and Hood, J. L. (2015b). Magnetic resonance imaging
of melanoma exosomes in lymph nodes. Magn. Reson. Med. 74, 266–271.
doi: 10.1002/mrm.25376
Huang, R., Qin, C., Wang, J., Hu, Y., Zheng, G., Qiu, G., et al. (2019). Differential
effects of extracellular vesicles from aging and young mesenchymal stem cells
in acute lung injury. Aging 11, 7996–8014. doi: 10.18632/aging.102314
Huber-Lang, M., Ignatius, A., and Brenner, R. E. (2015). Role of complement
on broken surfaces after trauma. Adv. Exp. Med. Biol. 865, 43–55.
doi: 10.1007/978-3-319-18603-0_3
Huber-Lang, M., Lambris, J. D., andWard, P. A. (2018). Innate immune responses
to trauma. Nat. Immunol. 19, 327–341. doi: 10.1038/s41590-018-0064-8
Hunter, D. J., Schofield, D., and Callander, E. (2014). The individual and
socioeconomic impact of osteoarthritis. Nat. Rev. Rheumatol. 10, 437–441.
doi: 10.1038/nrrheum.2014.44
Huynh, N., VonMoss, L., Smith, D., Rahman, I., Felemban, M. F., Zuo, J., et al.
(2016). Characterization of regulatory extracellular vesicles from osteoclasts. J.
Dent. Res. 95, 673–679. doi: 10.1177/0022034516633189
Hynes, K., Menicanin, D., Mrozik, K., Gronthos, S., and Bartold, P. M.
(2014). Generation of functional mesenchymal stem cells from different
induced pluripotent stem cell lines. Stem Cells Dev. 23, 1084–1096.
doi: 10.1089/scd.2013.0111
Issaq, H. J., Xiao, Z., and Veenstra, T. D. (2007). Serum and plasma proteomics.
Chem. Rev. 107, 3601–3620. doi: 10.1021/cr068287r
Janiszewski, M., do Carmo, A. O., Pedro, M. A., Silva, E., Knobel, E., and Laurindo,
F. R. M. (2004). Platelet-derived exosomes of septic individuals possess
proapoptotic NAD(P)H oxidase activity: a novel vascular redox pathway. Crit.
Care Med. 32, 818–825. doi: 10.1097/01.CCM.0000114829.17746.19
Jeon, O. H., Wilson, D. R., Clement, C. C., Rathod, S., Cherry, C., Powell,
B., et al. (2019). Senescence cell-associated extracellular vesicles serve
as osteoarthritis disease and therapeutic markers. Jci Insight 4:e125019.
doi: 10.1172/jci.insight.125019
Ji, L., Bao, L., Gu, Z., Zhou, Q., Liang, Y., Zheng, Y., et al. (2019). Comparison
of immunomodulatory properties of exosomes derived from bone marrow
mesenchymal stem cells and dental pulp stem cells. Immunol. Res. 67, 432–442.
doi: 10.1007/s12026-019-09088-6
Jia, Y., Zhu, Y., Qiu, S., Xu, J., and Chai, Y. (2019). Exosomes secreted by
endothelial progenitor cells accelerate bone regeneration during distraction
osteogenesis by stimulating angiogenesis. Stem Cell Res. Ther. 10:12.
doi: 10.1186/s13287-018-1115-7
Josephson, A. M., Bradaschia-Correa, V., Lee, S., Leclerc, K., Patel, K. S.,
Muinos Lopez, E., et al. (2019). Age-related inflammation triggers skeletal
stem/progenitor cell dysfunction. Proc. Natl. Acad. Sci. U.S.A. 116, 6995–7004.
doi: 10.1073/pnas.1810692116
Kang, R., Zhou, Y., Tan, S., Zhou, G., Aagaard, L., Xie, L., et al. (2015).
Mesenchymal stem cells derived from human induced pluripotent stem cells
retain adequate osteogenicity and chondrogenicity but less adipogenicity. Stem
Cell Res. Ther. 6:144. doi: 10.1186/s13287-015-0137-7
Kang, T., Jones, T. M., Naddell, C., Bacanamwo, M., Calvert, J. W., Thompson,
W. E., et al. (2016). Adipose-derived stem cells induce angiogenesis via
microvesicle transport of miRNA-31. Stem Cells Transl. Med. 5, 440–450.
doi: 10.5966/sctm.2015-0177
Karamanos, N. K., Theocharis, A. D., Neill, T., and Iozzo, R. V. (2019). Matrix
modeling and remodeling: a biological interplay regulating tissue homeostasis
and diseases.Matrix Biol. 75–76, 1–11. doi: 10.1016/j.matbio.2018.08.007
Karasu, E., Eisenhardt, S. U., Harant, J., and Huber-Lang, M. (2018).
Extracellular vesicles: packages sent with complement. Front. Immunol. 9:721.
doi: 10.3389/fimmu.2018.00721
Karimi, N., Cvjetkovic, A., Jang, S. C., Crescitelli, R., Hosseinpour Feizi, M. A.,
Nieuwland, R., et al. (2018). Detailed analysis of the plasma extracellular vesicle
proteome after separation from lipoproteins. Cell. Mol. Life Sci. 75, 2873–2886.
doi: 10.1007/s00018-018-2773-4
Kato, T., Miyaki, S., Ishitobi, H., Nakamura, Y., Nakasa, T., Lotz, M. K.,
et al. (2014). Exosomes from IL-1beta stimulated synovial fibroblasts induce
osteoarthritic changes in articular chondrocytes. Arthritis Res. Ther. 16:R163.
doi: 10.1186/ar4679
Kim, H., Lee, M. J., Bae, E. H., Ryu, J. S., Kaur, G., Kim, H. J., et al.
(2020). Comprehensive molecular profiles of functionally effective MSC-
derived extracellular vesicles in immunomodulation.Mol. Ther. 28, 1628–1644.
doi: 10.1016/j.ymthe.2020.04.020
Kim, S., Lee, S. K., Kim, H., and Kim, T. M. (2018). Exosomes secreted from
induced pluripotent stem cell-derived mesenchymal stem cells accelerate skin
cell proliferation. Int. J. Mol. Sci. 19:3119. doi: 10.3390/ijms19103119
Kirschner, K., Rattanavirotkul, N., Quince, M. F., and Chandra, T. (2020).
Functional heterogeneity in senescence. Biochem. Soc. Trans. 48, 765–773.
doi: 10.1042/BST20190109
Knijff-Dutmer, E. A., Koerts, J., Nieuwland, R., Kalsbeek-Batenburg, E. M., and van
de Laar, M. A. (2002). Elevated levels of platelet microparticles are associated
with disease activity in rheumatoid arthritis. Arthritis Rheum. 46, 1498–1503.
doi: 10.1002/art.10312
Koelling, S., Kruegel, J., Irmer, M., Path, J. R., Sadowski, B., Miro, X.,
et al. (2009). Migratory chondrogenic progenitor cells from repair tissue
during the later stages of human osteoarthritis. Cell Stem Cell 4, 324–335.
doi: 10.1016/j.stem.2009.01.015
Kolhe, R., Hunter, M., Liu, S., Jadeja, R. N., Pundkar, C., Mondal, A. K., et al.
(2017). Gender-specific differential expression of exosomal miRNA in synovial
fluid of patients with osteoarthritis. Sci. Rep. 7:2029. doi: 10.1038/s41598-017-
01905-y
Kordelas, L., Rebmann, V., Ludwig, A. K., Radtke, S., Ruesing, J., Doeppner, T. R.,
et al. (2014). MSC-derived exosomes: a novel tool to treat therapy-refractory
graft-versus-host disease. Leukemia 28, 970–973. doi: 10.1038/leu.2014.41
Kornilov, R., Puhka, M., Mannerström, B., Hiidenmaa, H., Peltoniemi, H.,
Siljander, P., et al. (2018). Efficient ultrafiltration-based protocol to deplete
extracellular vesicles from fetal bovine serum. J. Extracell. Vesicles 7:1422674.
doi: 10.1080/20013078.2017.1422674
Koyama, N., Miura, M., Nakao, K., Kondo, E., Fujii, T., Taura, D., et al. (2013).
Human induced pluripotent stem cells differentiated into chondrogenic lineage
via generation of mesenchymal progenitor cells. Stem Cells Dev. 22, 102–113.
doi: 10.1089/scd.2012.0127
Kreuser, U., Buchert, J., Haase, A., Richter, W., and Diederichs, S. (2020).
Initial WNT/beta-catenin activation enhanced mesoderm commitment,
extracellular matrix expression, cell aggregation and cartilage tissue yield
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 23 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
from induced pluripotent stem cells. Front. Cell Dev. Biol. 8:581331.
doi: 10.3389/fcell.2020.581331
Kuang,M. J., Huang, Y., Zhao, X. G., Zhang, R., Ma, J. X.,Wang, D. C., et al. (2019).
Exosomes derived from wharton’s jelly of human umbilical cord mesenchymal
stem cells reduce osteocyte apoptosis in glucocorticoid-induced osteonecrosis
of the femoral head in rats via the miR-21-PTEN-AKT signalling pathway. Int.
J. Biol. Sci. 15, 1861–1871. doi: 10.7150/ijbs.32262
Kusuma, G. D., Carthew, J., Lim, R., and Frith, J. E. (2017). Effect of
the microenvironment on mesenchymal stem cell paracrine signaling:
opportunities to engineer the therapeutic effect. Stem Cells Dev. 26, 617–631.
doi: 10.1089/scd.2016.0349
Lai, R. C., Tan, S. S., Teh, B. J., Sze, S. K., Arslan, F., de Kleijn, D. P., et al.
(2012). Proteolytic potential of the MSC exosome proteome: implications for
an exosome-mediated delivery of therapeutic proteasome. Int. J. Proteomics
2012:971907. doi: 10.1155/2012/971907
Lamparski, H. G., Metha-Damani, A., Yao, J. Y., Patel, S., Hsu, D. H.,
Ruegg, C., et al. (2002). Production and characterization of clinical grade
exosomes derived from dendritic cells. J. Immunol. Methods 270, 211–226.
doi: 10.1016/S0022-1759(02)00330-7
Lang, S., Herrmann, M., Pfeifer, C., Brockhoff, G., Zellner, J., Nerlich,
M., et al. (2017). Leukocyte-reduced platelet-rich plasma stimulates the
in vitro proliferation of adipose-tissue derived mesenchymal stem cells
depending on PDGF signaling. Clin. Hemorheol. Microcirc. 67, 183–196.
doi: 10.3233/CH-170246
Lang, S., Loibl, M., and Herrmann, M. (2018). Platelet-rich plasma
in tissue engineering: hype and hope. Eur. Surg. Res. 59, 265–275.
doi: 10.1159/000492415
Lässer, C., Eldh, M., and Lötvall, J. (2012). Isolation and characterization of
RNA-containing exosomes. J. Vis. Exp. 59:e3037. doi: 10.3791/3037
Lee, B. C., and Yu, K. R. (2020). Impact of mesenchymal stem cell senescence on
inflammaging. BMB Rep. 53, 65–73. doi: 10.5483/BMBRep.2020.53.2.291
Lehrich, B. M., Liang, Y., Khosravi, P., Federoff, H. J., and Fiandaca, M. S. (2018).
Fetal bovine serum-derived extracellular vesicles persist within vesicle-depleted
culture media. Int. J. Mol. Sci. 19:3538. doi: 10.3390/ijms19113538
Li, D., Liu, J., Guo, B., Liang, C., Dang, L., Lu, C., et al. (2016). Osteoclast-derived
exosomal miR-214-3p inhibits osteoblastic bone formation. Nat. Commun.
7:10872. doi: 10.1038/ncomms10872
Li, F., Bronson, S., and Niyibizi, C. (2010). Derivation of murine induced
pluripotent stem cells (iPS) and assessment of their differentiation toward
osteogenic lineage. J. Cell. Biochem. 109, 643–652. doi: 10.1002/jcb.22440
Li, J., Zhang, Y., Liu, Y., Dai, X., Li,W., Cai, X., et al. (2013). Microvesicle-mediated
transfer of microRNA-150 from monocytes to endothelial cells promotes
angiogenesis. J. Biol. Chem. 288, 23586–23596. doi: 10.1074/jbc.M113.489302
Li, P., Kaslan, M., Lee, S. H., Yao, J., and Gao, Z. (2017). Progress in exosome
isolation techniques. Theranostics 7, 789–804. doi: 10.7150/thno.18133
Li, W., Liu, Y., Zhang, P., Tang, Y., Zhou, M., Jiang, W., et al. (2018).
Tissue-engineered bone immobilized with human adipose stem cells-derived
exosomes promotes bone regeneration. ACS Appl. Mater. Interfaces 10,
5240–5254. doi: 10.1021/acsami.7b17620
Lian, Q., Zhang, Y., Zhang, J., Zhang, H. K., Wu, X., Lam, F. F., et al. (2010).
Functional mesenchymal stem cells derived from human induced pluripotent
stem cells attenuate limb ischemia in mice. Circulation 121, 1113–1123.
doi: 10.1161/CIRCULATIONAHA.109.898312
Liang, X., Zhang, L., Wang, S., Han, Q., and Zhao, R. C. (2016). Exosomes
secreted by mesenchymal stem cells promote endothelial cell angiogenesis by
transferring miR-125a. J. Cell Sci. 129, 2182–2189. doi: 10.1242/jcs.170373
Lieberthal, J., Sambamurthy, N., and Scanzello, C. R. (2015). Inflammation in joint
injury and post-traumatic osteoarthritis. Osteoarthr. Cartil. 23, 1825–1834.
doi: 10.1016/j.joca.2015.08.015
Liu, S., Mahairaki, V., Bai, H., Ding, Z., Li, J., Witwer, K. W., et al. (2019).
Highly purified human extracellular vesicles produced by stem cells alleviate
aging cellular phenotypes of senescent human cells. Stem Cells 37, 779–790.
doi: 10.1002/stem.2996
Liu, W., Li, L., Rong, Y., Qian, D., Chen, J., Zhou, Z., et al. (2020).
Hypoxic mesenchymal stem cell-derived exosomes promote bone
fracture healing by the transfer of miR-126. Acta Biomater. 103, 196–212.
doi: 10.1016/j.actbio.2019.12.020
Liu, X., Li, Q., Niu, X., Hu, B., Chen, S., Song, W., et al. (2017a). Exosomes secreted
from human-induced pluripotent stem cell-derived mesenchymal stem cells
prevent osteonecrosis of the femoral head by promoting angiogenesis. Int. J.
Biol. Sci. 13, 232–244. doi: 10.7150/ijbs.16951
Liu, X. L., Yang, Y. L., Li, Y., Niu, X., Zhao, B. Z., Wang, Y., et al. (2017b).
Integration of stem cell-derived exosomes with in situ hydrogel glue as
a promising tissue patch for articular cartilage regeneration. Nanoscale 9,
4430–4438. doi: 10.1039/C7NR00352H
Lo Cicero, A., Majkowska, I., Nagase, H., Di Liegro, I., and Troeberg, L.
(2012). Microvesicles shed by oligodendroglioma cells and rheumatoid
synovial fibroblasts contain aggrecanase activity. Matrix Biol. 31, 229–233.
doi: 10.1016/j.matbio.2012.02.005
Lo Sicco, C., Reverberi, D., Balbi, C., Ulivi, V., Principi, E., Pascucci, L., et al.
(2017). Mesenchymal stem cell-derived extracellular vesicles as mediators of
anti-inflammatory effects: endorsement of macrophage polarization. Stem Cells
Transl. Med. 6, 1018–1028. doi: 10.1002/sctm.16-0363
Lobb, R., and Möller, A. (2017). Size exclusion chromatography: a simple and
reliable method for exosome purification. Methods Mol. Biol. 1660, 105–110.
doi: 10.1007/978-1-4939-7253-1_9
Loeser, R. F., Goldring, S. R., Scanzello, C. R., and Goldring, M. B. (2012).
Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum. 64,
1697–1707. doi: 10.1002/art.34453
Loi, F., Cordova, L. A., Pajarinen, J., Lin, T. H., Yao, Z., and Goodman,
S. B. (2016). Inflammation, fracture and bone repair. Bone 86, 119–130.
doi: 10.1016/j.bone.2016.02.020
Loibl, M., Lang, S., Hanke, A., Herrmann, M., Huber, M., Brockhoff, G., et al.
(2016). Leukocyte-reduced platelet-rich plasma alters protein expression of
adipose tissue-derived mesenchymal stem cells. Plast. Reconstr. Surg. 138,
397–408. doi: 10.1097/PRS.0000000000002388
Lombardo, G., Dentelli, P., Togliatto, G., Rosso, A., Gili, M., Gallo, S., et al.
(2016). Activated Stat5 trafficking via endothelial cell-derived extracellular
vesicles controls IL-3 pro-angiogenic paracrine action. Sci. Rep. 6:25689.
doi: 10.1038/srep25689
Lopatina, T., Bruno, S., Tetta, C., Kalinina, N., Porta, M., and Camussi, G. (2014).
Platelet-derived growth factor regulates the secretion of extracellular vesicles by
adipose mesenchymal stem cells and enhances their angiogenic potential. Cell
Commun. Signal. 12:26. doi: 10.1186/1478-811X-12-26
Lotvall, J., Hill, A. F., Hochberg, F., Buzas, E. I., Di Vizio, D., Gardiner, C.,
et al. (2014). Minimal experimental requirements for definition of extracellular
vesicles and their functions: a position statement from the international society
for extracellular vesicles. J. Extracell. Vesicles 3:26913. doi: 10.3402/jev.v3.26913
Ludwig, A. K., De Miroschedji, K., Doeppner, T. R., Börger, V., Ruesing, J.,
Rebmann, V., et al. (2018). Precipitation with polyethylene glycol followed
by washing and pelleting by ultracentrifugation enriches extracellular vesicles
from tissue culture supernatants in small and large scales. J. Extracell. Vesicles
7:1528109. doi: 10.1080/20013078.2018.1528109
Luo, Z., Shang, X., Zhang, H., Wang, G., Massey, P. A., Barton, S. R., et al. (2019).
Notch signaling in osteogenesis, osteoclastogenesis, and angiogenesis. Am. J.
Pathol. 189, 1495–1500. doi: 10.1016/j.ajpath.2019.05.005
Lv, C. Y., Ding, W. J., Wang, Y. L., Zhao, Z. Y., Li, J. H., Chen, Y., et al. (2018). A
PEG-based method for the isolation of urinary exosomes and its application in
renal fibrosis diagnostics using cargo miR-29c and miR-21 analysis. Int. Urol.
Nephrol. 50, 973–982. doi: 10.1007/s11255-017-1779-4
Ma, J., Zhao, Y., Sun, L., Sun, X., Zhao, X., Sun, X., et al. (2017). Exosomes derived
from akt-modified human umbilical cord mesenchymal stem cells improve
cardiac regeneration and promote angiogenesis via activating platelet-derived
growth factor D. Stem Cells Transl. Med. 6, 51–59. doi: 10.5966/sctm.2016-0038
Maas, S. L. N., de Vrij, J., van der Vlist, E. J., Geragousian, B., van Bloois,
L., Mastrobattista, E., et al. (2015). Possibilities and limitations of current
technologies for quantification of biological extracellular vesicles and synthetic
mimics. J. Control. Release 200, 87–96. doi: 10.1016/j.jconrel.2014.12.041
Maeda, Y., Farina, N. H., Matzelle, M. M., Fanning, P. J., Lian, J. B., and Gravallese,
E. M. (2017). Synovium-derived microRNAs regulate bone pathways in
rheumatoid arthritis. J. Bone Miner. Res. 32, 461–472. doi: 10.1002/jbmr.3005
Malda, J., Boere, J., van de Lest, C. H., van Weeren, P., and Wauben, M. H. (2016).
Extracellular vesicles - new tool for joint repair and regeneration. Nat Rev.
Rheumatol. 12, 243–249. doi: 10.1038/nrrheum.2015.170
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 24 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
Mao, G., Zhang, Z., Hu, S., Zhang, Z., Chang, Z., Huang, Z., et al. (2018). Exosomes
derived from miR-92a-3p-overexpressing human mesenchymal stem cells
enhance chondrogenesis and suppress cartilage degradation via targeting
WNT5A. Stem Cell Res. Ther. 9:247. doi: 10.1186/s13287-018-1004-0
Martin-Rufino, J. D., Espinosa-Lara, N., Osugui, L., and Sanchez-Guijo, F.
(2019). Targeting the immune system with mesenchymal stromal cell-derived
extracellular vesicles: what is the cargo’s mechanism of action? Front. Bioeng.
Biotechnol. 7:308. doi: 10.3389/fbioe.2019.00308
Masaoutis, C., and Theocharis, S. (2019). The role of exosomes in bone remodeling:
implications for bone physiology and disease. Dis. Markers. 2019:9417914.
doi: 10.1155/2019/9417914
Maumus, M., Rozier, P., Boulestreau, J., Jorgensen, C., and Noel, D.
(2020). mesenchymal stem cell-derived extracellular vesicles: opportunities
and challenges for clinical translation. Front. Bioeng. Biotechnol. 8:997.
doi: 10.3389/fbioe.2020.00997
McKelvey, K. J., Powell, K. L., Ashton, A. W., Morris, J. M., and McCracken,
S. A. (2015). Exosomes: mechanisms of uptake. J. Circ. Biomark. 4:7.
doi: 10.33393/jcb.2015.2057
Melidoni, A. (2020). Small extracellular vesicles combat senescence. Nat. Rev. Mol.
Cell Biol. 21, 498–499. doi: 10.1038/s41580-020-0271-7
Mianehsaz, E., Mirzaei, H. R., Mahjoubin-Tehran, M., Rezaee, A., Sahebnasagh,
R., Pourhanifeh, M. H., et al. (2019). Mesenchymal stem cell-derived exosomes:
a new therapeutic approach to osteoarthritis? Stem Cell Res. Ther. 10:340.
doi: 10.1186/s13287-019-1445-0
Moballegh Nasery, M., Abadi, B., Poormoghadam, D., Zarrabi, A., Keyhanvar,
P., Khanbabaei, H., et al. (2020). Curcumin delivery mediated by bio-based
nanoparticles: a review.Molecules 25:689. doi: 10.3390/molecules25030689
Mokarizadeh, A., Delirezh, N., Morshedi, A., Mosayebi, G., Farshid, A. A., and
Mardani, K. (2012).Microvesicles derived frommesenchymal stem cells: potent
organelles for induction of tolerogenic signaling. Immunol. Lett. 147, 47–54.
doi: 10.1016/j.imlet.2012.06.001
Momen-Heravi, F. (2017). Isolation of extracellular vesicles by ultracentrifugation.
Methods Mol. Biol. 1660, 25–32. doi: 10.1007/978-1-4939-7253-1_3
Monguio-Tortajada, M., Galvez-Monton, C., Bayes-Genis, A., Roura, S., and
Borras, F. E. (2019). Extracellular vesicle isolation methods: rising impact
of size-exclusion chromatography. Cell. Mol. Life Sci. 76, 2369–2382.
doi: 10.1007/s00018-019-03071-y
Monguio-Tortajada, M., Roura, S., Galvez-Monton, C., Pujal, J. M., Aran, G.,
Sanjurjo, L., et al. (2017). Nanosized UCMSC-derived extracellular vesicles
but not conditioned medium exclusively inhibit the inflammatory response
of stimulated T cells: implications for nanomedicine. Theranostics 7, 270–284.
doi: 10.7150/thno.16154
Morrison, T. J., Jackson, M. V., Cunningham, E. K., Kissenpfennig, A., McAuley,
D. F., O’Kane, C. M., et al. (2017). Mesenchymal stromal cells modulate
macrophages in clinically relevant lung injury models by extracellular vesicle
mitochondrial transfer. Am. J. Respir. Crit. Care Med. 196, 1275–1286.
doi: 10.1164/rccm.201701-0170OC
Murphy, C., Withrow, J., Hunter, M., Liu, Y., Tang, Y. L., Fulzele, S., et al. (2018).
Emerging role of extracellular vesicles in musculoskeletal diseases.Mol. Aspects
Med. 60, 123–128. doi: 10.1016/j.mam.2017.09.006
Muschler, G. F., Nitto, H., Boehm, C. A., and Easley, K. A. (2001). Age-
and gender-related changes in the cellularity of human bone marrow and
the prevalence of osteoblastic progenitors. J. Orthop. Res. 19, 117–125.
doi: 10.1016/S0736-0266(00)00010-3
Ng, C. T., Biniecka, M., Kennedy, A., McCormick, J., Fitzgerald, O., Bresnihan, B.,
et al. (2010). Synovial tissue hypoxia and inflammation in vivo. Ann. Rheum.
Dis. 69, 1389–1395. doi: 10.1136/ard.2009.119776
Ni, Z., Kuang, L., Chen, H., Xie, Y., Zhang, B., Ouyang, J., et al. (2019).
The exosome-like vesicles from osteoarthritic chondrocyte enhanced
mature IL-1beta production of macrophages and aggravated synovitis
in osteoarthritis. Cell Death Dis. 10:522. doi: 10.1038/s41419-019-
1739-2
Nie, Y., Sato, Y., Garner, R. T., Kargl, C., Wang, C., Kuang, S., et al. (2019). Skeletal
muscle-derived exosomes regulate endothelial cell functions via reactive
oxygen species-activated nuclear factor-kappaB signalling. Exp. Physiol. 104,
1262–1273. doi: 10.1113/EP087396
Nong, K., Wang, W., Niu, X., Hu, B., Ma, C., Bai, Y., et al. (2016).
Hepatoprotective effect of exosomes from human-induced pluripotent stem
cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion
injury in rats. Cytotherapy 18, 1548–1559. doi: 10.1016/j.jcyt.2016.08.002
Oksvold, M. P., Neurauter, A., and Pedersen, K. W. (2015). Magnetic
bead-based isolation of exosomes. Methods Mol. Biol. 1218, 465–481.
doi: 10.1007/978-1-4939-1538-5_27
Oryan, A., Kamali, A., Moshiri, A., and Baghaban Eslaminejad, M. (2017). Role of
mesenchymal stem cells in bone regenerative medicine: what is the evidence?
Cells Tissues Organs. 204, 59–83. doi: 10.1159/000469704
Park, S. J., Kim, J. M., Kim, J., Hur, J., Park, S., Kim, K., et al. (2018). Molecular
mechanisms of biogenesis of apoptotic exosome-like vesicles and their roles
as damage-associated molecular patterns. Proc. Natl. Acad. Sci. U.S.A. 115,
E11721–E11730. doi: 10.1073/pnas.1811432115
Patel, D. B., Gray, K. M., Santharam, Y., Lamichhane, T. N., Stroka, K. M.,
and Jay, S. M. (2017). Impact of cell culture parameters on production
and vascularization bioactivity of mesenchymal stem cell-derived extracellular
vesicles. Bioeng. Transl. Med. 2, 170–179. doi: 10.1002/btm2.10065
Patel, D. B., Luthers, C. R., Lerman, M. J., Fisher, J. P., and Jay, S. M.
(2019). Enhanced extracellular vesicle production and ethanol-mediated
vascularization bioactivity via a 3D-printed scaffold-perfusion bioreactor
system. Acta Biomater. 95, 236–244. doi: 10.1016/j.actbio.2018.11.024
Pérez-González, R., Gauthier, S. A., Kumar, A., Saito, M., Saito, M., and Levy, E.
(2017). A Method for isolation of extracellular vesicles and characterization
of exosomes from brain extracellular space. Methods Mol. Biol. 1545, 139–151.
doi: 10.1007/978-1-4939-6728-5_10
Petho, A., Chen, Y., and George, A. (2018). Exosomes in extracellular matrix bone
biology. Curr. Osteoporos. Rep. 16, 58–64. doi: 10.1007/s11914-018-0419-y
Poellmann, M. J., Nair, A., Bu, J., Kim, J. K. H., Kimple, R. J., and
Hong, S. (2020). Immunoavidity-based capture of tumor exosomes
using poly(amidoamine) dendrimer surfaces. Nano Lett. 20, 5686–5692.
doi: 10.1021/acs.nanolett.0c00950
Prada, I., and Meldolesi, J. (2016). Binding and fusion of extracellular vesicles
to the plasma membrane of their cell targets. Int. J. Mol. Sci. 17:1296.
doi: 10.3390/ijms17081296
Qi, X., Zhang, J., Yuan, H., Xu, Z., Li, Q., Niu, X., et al. (2016). Exosomes
secreted by human-induced pluripotent stem cell-derived mesenchymal
stem cells repair critical-sized bone defects through enhanced angiogenesis
and osteogenesis in osteoporotic rats. Int. J. Biol. Sci. 12, 836–849.
doi: 10.7150/ijbs.14809
Qin, Y., Peng, Y., Zhao, W., Pan, J., Ksiezak-Reding, H., Cardozo, C., et al. (2017).
Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived
exosomal microRNA-218: a novel mechanism in muscle-bone communication.
J. Biol. Chem. 292, 11021–11033. doi: 10.1074/jbc.M116.770941
Qin, Y., Wang, L., Gao, Z., Chen, G., and Zhang, C. (2016). Bone marrow
stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and
differentiation in vitro and promote bone regeneration in vivo. Sci. Rep.
6:21961. doi: 10.1038/srep21961
Raggatt, L. J., and Partridge, N. C. (2010). Cellular and molecular
mechanisms of bone remodeling. J. Biol. Chem. 285, 25103–25108.
doi: 10.1074/jbc.R109.041087
Ramasubramanian, L., Kumar, P., and Wang, A. (2019). Engineering extracellular
vesicles as nanotherapeutics for regenerative medicine. Biomolecules 10:48.
doi: 10.3390/biom10010048
Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles:
exosomes, microvesicles, and friends. J. Cell Biol. 200, 373–383.
doi: 10.1083/jcb.201211138
Reis, M., Mavin, E., Nicholson, L., Green, K., Dickinson, A. M., and
Wang, X. N. (2018). Mesenchymal stromal cell-derived extracellular vesicles
attenuate dendritic cell maturation and function. Front. Immunol. 9:2538.
doi: 10.3389/fimmu.2018.02538
Ricklin, D., Hajishengallis, G., Yang, K., and Lambris, J. D. (2010). Complement:
a key system for immune surveillance and homeostasis. Nat. Immunol. 11,
785–797. doi: 10.1038/ni.1923
Rider,M. A., Hurwitz, S. N., andMeckes, D. G. Jr. (2016). ExtraPEG: a polyethylene
glycol-based method for enrichment of extracellular vesicles. Sci. Rep. 6:23978.
doi: 10.1038/srep23978
Riegger, J., and Brenner, R. E. (2019). Evidence of necroptosis in osteoarthritic
disease: investigation of blunt mechanical impact as possible trigger in
regulated necrosis. Cell Death Dis. 10:683. doi: 10.1038/s41419-019-1930-5
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 25 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
Riegger, J., and Brenner, R. E. (2020). Pathomechanisms of posttraumatic
osteoarthritis: chondrocyte behavior and fate in a precarious environment. Int.
J. Mol. Sci. 21:1560. doi: 10.3390/ijms21051560
Riegger, J., Huber-Lang, M., and Brenner, R. E. (2020). Crucial role of the terminal
complement complex in chondrocyte death and hypertrophy after cartilage
trauma. Osteoarthr. Cartil. 28, 685–697. doi: 10.1016/j.joca.2020.01.004
Riegger, J., Palm, H. G., and Brenner, R. E. (2018). The functional role of
chondrogenic stem/progenitor cells: novel evidence for immunomodulatory
properties and regenerative potential after cartilage injury. Eur. Cell. Mater. 36,
110–127. doi: 10.22203/eCM.v036a09
Rilla, K., Mustonen, A. M., Arasu, U. T., Härkönen, K., Matilainen, J.,
and Nieminen, P. (2019). Extracellular vesicles are integral and functional
components of the extracellular matrix. Matrix Biol. 75–76, 201–219.
doi: 10.1016/j.matbio.2017.10.003
Robbins, P. D., and Morelli, A. E. (2014). Regulation of immune responses by
extracellular vesicles. Nat. Rev. Immunol. 14, 195–208. doi: 10.1038/nri3622
Rodriguez-Carrio, J., Alperi-Lopez, M., Lopez, P., Alonso-Castro, S., Carro-
Esteban, S. R., Ballina-Garcia, F. J., et al. (2015). Altered profile of circulating
microparticles in rheumatoid arthritis patients. Clin. Sci. 128, 437–448.
doi: 10.1042/CS20140675
Ruwald, J. M., Randau, T. M., Hilgers, C., Masson, W., Irsen, S., Eymael, R. L., et al.
(2020). Extracellular vesicle isolation and characterization from periprosthetic
joint synovial fluid in revision total joint arthroplasty. J. Clin. Med. 9:516.
doi: 10.3390/jcm9020516
Sabry, D., Shamaa, A., Amer, M., El-Tookhy, O., Abdallah, A., El Hassib, D. M.
A., et al. (2018). The effect of mesenchymal sCell derived microvesicles in
repair of femoral chondral defects in dogs. J. Musculoskelet. Res. 21:1850006.
doi: 10.1142/S0218957718500069
Sacchetti, B., Funari, A., Remoli, C., Giannicola, G., Kogler, G., Liedtke, S., et al.
(2016). No identical “mesenchymal stem cells” at different times and sites:
human committed progenitors of distinct origin and differentiation potential
are incorporated as adventitial cells in microvessels. Stem Cell Rep. 6, 897–913.
doi: 10.1016/j.stemcr.2016.05.011
Salama, R., Sadaie, M., Hoare, M., and Narita, M. (2014). Cellular senescence and
its effector programs. Genes Dev. 28, 99–114. doi: 10.1101/gad.235184.113
Sanderson, R. D., Bandari, S. K., and Vlodavsky, I. (2019). Proteases
and glycosidases on the surface of exosomes: newly discovered
mechanisms for extracellular remodeling. Matrix Biol. 75–76, 160–169.
doi: 10.1016/j.matbio.2017.10.007
Sato, M., Suzuki, T., Kawano, M., and Tamura, M. (2017). Circulating osteocyte-
derived exosomes contain miRNAs which are enriched in exosomes from
MLO-Y4 cells. Biomed Rep. 6, 223–231. doi: 10.3892/br.2016.824
Seol, D., McCabe, D. J., Choe, H., Zheng, H. J., Yu, Y., Jang, K., et al. (2012).
Chondrogenic progenitor cells respond to cartilage injury. Arthritis Rheum-Us
64, 3626–3637. doi: 10.1002/art.34613
Shabbir, A., Cox, A., Rodriguez-Menocal, L., Salgado, M., and Van Badiavas, E.
(2015). Mesenchymal stem cell exosomes induce proliferation and migration of
normal and chronic wound fibroblasts, and enhance angiogenesis in vitro. Stem
Cells Dev. 24, 1635–1647. doi: 10.1089/scd.2014.0316
Shelke, G. V., Lässer, C., Gho, Y. S., and Lötvall, J. (2014). Importance of
exosome depletion protocols to eliminate functional and RNA-containing
extracellular vesicles from fetal bovine serum. J. Extracell. Vesicles
3:10.3402/jev.v3403.24783. doi: 10.3402/jev.v3.24783
Shimoda, M., and Khokha, R. (2013). Proteolytic factors in exosomes. Proteomics
13, 1624–1636. doi: 10.1002/pmic.201200458
Shimoda, M., and Khokha, R. (2017). Metalloproteinases in extracellular
vesicles. Biochim. Biophys. Mol. Cell Res. 1864, 1989–2000.
doi: 10.1016/j.bbamcr.2017.05.027
Shlomovitz, I., Yanovich-Arad, G., Erlich, Z., Edry-Botzer, L., Zargarian, S., Cohen,
H., et al. (2020). Proteomic analysis of necroptotic extracellular vesicles. bioRxiv
doi: 10.1101/2020.04.11.037192
Siegel, G., Schafer, R., and Dazzi, F. (2009). The
immunosuppressive properties of mesenchymal stem cells.
Transplantation 87, S45–49. doi: 10.1097/TP.0b013e3181a
285b0
Skriner, K., Adolph, K., Jungblut, P. R., and Burmester, G. R. (2006). Association of
citrullinated proteins with synovial exosomes. Arthritis Rheum. 54, 3809–3814.
doi: 10.1002/art.22276
Sódar, B. W., Kittel, Á., Pálóczi, K., Vukman, K. V., Osteikoetxea, X., Szabó-
Taylor, K., et al. (2016). Low-density lipoprotein mimics blood plasma-derived
exosomes and microvesicles during isolation and detection. Sci. Rep. 6:24316.
doi: 10.1038/srep24316
Spitzhorn, L. S., Megges, M., Wruck, W., Rahman, M. S., Otte, J., Degistirici,
O., et al. (2019). Human iPSC-derived MSCs (iMSCs) from aged
individuals acquire a rejuvenation signature. Stem Cell Res. Ther. 10:100.
doi: 10.1186/s13287-019-1209-x
Stolberg-Stolberg, J., Sambale, M., Hansen, U., Schäfer, A., Raschke, M.,
Bertrand, J., et al. (2020). Cartilage trauma induces necroptotic chondrocyte
death and expulsion of cellular contents. Int. J. Mol. Sci. 21:4204.
doi: 10.3390/ijms21124204
Street, J. M., Koritzinsky, E. H., Glispie, D. M., and Yuen, P. S. T. (2017). Urine
exosome isolation and characterization. Methods Mol. Biol. 1641, 413–423.
doi: 10.1007/978-1-4939-7172-5_23
Sumida, M., Hane, M., Yabe, U., Shimoda, Y., Pearce, O. M., Kiso, M., et al.
(2015). Rapid Trimming of cell surface polysialic acid (PolySia) by exovesicular
sialidase triggers release of preexisting surface neurotrophin. J. Biol. Chem. 290,
13202–13214. doi: 10.1074/jbc.M115.638759
Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., et al. (2010). A novel
nanoparticle drug delivery system: the anti-inflammatory activity of curcumin
is enhanced when encapsulated in exosomes. Mol. Ther. 18, 1606–1614.
doi: 10.1038/mt.2010.105
Tabar, V., and Studer, L. (2014). Pluripotent stem cells in regenerative
medicine: challenges and recent progress. Nat. Rev. Genet. 15, 82–92.
doi: 10.1038/nrg3563
Takahashi, A., Okada, R., Nagao, K., Kawamata, Y., Hanyu, A., Yoshimoto, S., et al.
(2017). Exosomes maintain cellular homeostasis by excreting harmful DNA
from cells. Nat. Commun. 8:15287. doi: 10.1038/ncomms15287
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., et al.
(2007). Induction of pluripotent stem cells from adult human fibroblasts by
defined factors. Cell 131, 861–872. doi: 10.1016/j.cell.2007.11.019
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from
mouse embryonic and adult fibroblast cultures by defined factors. Cell 126,
663–676. doi: 10.1016/j.cell.2006.07.024
Takasugi, M. (2018). Emerging roles of extracellular vesicles in cellular senescence
and aging. Aging Cell 17:e12734. doi: 10.1111/acel.12734
Tan, E., Asada, H. H., and Ge, R. (2018). Extracellular vesicle-carried jagged-
1 inhibits HUVEC sprouting in a 3D microenvironment. Angiogenesis 21,
571–580. doi: 10.1007/s10456-018-9609-6
Tan, S. H. S., Wong, J. R. Y., Sim, S. J. Y., Tjio, C. K. E., Wong, K. L., Chew,
J. R. J., et al. (2020). Mesenchymal stem cell exosomes in bone regenerative
strategies-a systematic review of preclinical studies.Mater. Today Bio 7:100067.
doi: 10.1016/j.mtbio.2020.100067
Tang, H., He, Y., Li, L., Mao, W., Chen, X., Ni, H., et al. (2019).
Exosomal MMP2 derived from mature osteoblasts promotes angiogenesis of
endothelial cells via VEGF/Erk1/2 signaling pathway. Exp. Cell Res. 383:11541.
doi: 10.1016/j.yexcr.2019.111541
Tao, S. C., Yuan, T., Zhang, Y. L., Yin, W. J., Shang-Chun, G., and Zhang,
C. Q. (2017). Exosomes derived from miR-140-5p-overexpressing human
synovial mesenchymal stem cells enhance cartilage tissue regeneration and
prevent osteoarthritis of the knee in a rat model. Theranostics 7, 180–195.
doi: 10.7150/thno.17133
Taraboletti, G., D’Ascenzo, S., Borsotti, P., Giavazzi, R., Pavan, A., and
Dolo, V. (2002). Shedding of the matrix metalloproteinases MMP-2,
MMP-9, and MT1-MMP as membrane vesicle-associated components by
endothelial cells. Am. J. Pathol. 160, 673–680. doi: 10.1016/S0002-9440(10)
64887-0
Tauro, B. J., Greening, D. W., Mathias, R. A., Ji, H., Mathivanan, S.,
Scott, A. M., et al. (2012). Comparison of ultracentrifugation, density
gradient separation, and immunoaffinity capture methods for isolating human
colon cancer cell line LIM1863-derived exosomes. Methods 56, 293–304.
doi: 10.1016/j.ymeth.2012.01.002
Taylor, D. D., and Shah, S. (2015). Methods of isolating extracellular
vesicles impact down-stream analyses of their cargoes. Methods 87, 3–10.
doi: 10.1016/j.ymeth.2015.02.019
Terlecki-Zaniewicz, L., Lammermann, I., Latreille, J., Bobbili, M. R., Pils, V.,
Schosserer, M., et al. (2018). Small extracellular vesicles and their miRNA cargo
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 26 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
are anti-apoptotic members of the senescence-associated secretory phenotype.
Aging 10, 1103–1132. doi: 10.18632/aging.101452
Thery, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D.,
Andriantsitohaina, R., et al. (2018). Minimal information for studies
of extracellular vesicles 2018 (MISEV2018): a position statement of the
international society for extracellular vesicles and update of the MISEV2014
guidelines. J. Extracell. Vesicles 7:1535750. doi: 10.1080/20013078.2018.1535750
Thery, C., Zitvogel, L., and Amigorena, S. (2002). Exosomes: composition,
biogenesis and function. Nat. Rev. Immunol. 2, 569–579. doi: 10.1038/nri855
Ti, D., Hao, H., Tong, C., Liu, J., Dong, L., Zheng, J., et al. (2015). LPS-
preconditioned mesenchymal stromal cells modify macrophage polarization
for resolution of chronic inflammation via exosome-shuttled let-7b. J. Transl.
Med. 13:308. doi: 10.1186/s12967-015-0642-6
To, K., Romain, K., Mak, C., Kamaraj, A., Henson, F., and Khan, W. (2020). The
treatment of cartilage damage using human mesenchymal stem cell-derived
extracellular vesicles: a systematic review of in vivo studies. Front. Bioeng.
Biotechnol. 8:580. doi: 10.3389/fbioe.2020.00580
Todorova, D., Simoncini, S., Lacroix, R., Sabatier, F., and Dignat-George, F.
(2017). Extracellular vesicles in angiogenesis. Circ. Res. 120, 1658–1673.
doi: 10.1161/CIRCRESAHA.117.309681
Tofino-Vian, M., Guillen, M. I., Perez Del Caz, M. D., Silvestre, A., and Alcaraz, M.
J. (2018). Microvesicles from human adipose tissue-derived mesenchymal stem
cells as a new protective strategy in osteoarthritic chondrocytes. Cell. Physiol.
Biochem. 47, 11–25. doi: 10.1159/000489739
Toh, W. S., Lai, R. C., Hui, J. H. P., and Lim, S. K. (2017). MSC exosome as a
cell-free MSC therapy for cartilage regeneration: implications for osteoarthritis
treatment. Semin. Cell Dev. Biol. 67, 56–64. doi: 10.1016/j.semcdb.2016.11.008
Toh, W. S., Zhang, B., Lai, R. C., and Lim, S. K. (2018). Immune regulatory targets
of mesenchymal stromal cell exosomes/small extracellular vesicles in tissue
regeneration. Cytotherapy 20, 1419–1426. doi: 10.1016/j.jcyt.2018.09.008
Vallabhaneni, K. C., Penfornis, P., Dhule, S., Guillonneau, F., Adams, K. V., Mo,
Y. Y., et al. (2015). Extracellular vesicles from bone marrow mesenchymal
stem/stromal cells transport tumor regulatory microRNA, proteins, and
metabolites. Oncotarget 6, 4953–4967. doi: 10.18632/oncotarget.3211
van Balkom, B. W., de Jong, O. G., Smits, M., Brummelman, J., den Ouden,
K., de Bree, P. M., et al. (2013). Endothelial cells require miR-214 to
secrete exosomes that suppress senescence and induce angiogenesis in
human and mouse endothelial cells. Blood 121, 3997–4006, S3991–S3915.
doi: 10.1182/blood-2013-02-478925
van den Akker, F., Vrijsen, K. R., Deddens, J. C., Buikema, J. W., Mokry, M., van
Laake, L. W., et al. (2018). Suppression of T cells by mesenchymal and cardiac
progenitor cells is partly mediated via extracellular vesicles. Heliyon 4:e00642.
doi: 10.1016/j.heliyon.2018.e00642
Walter, S. G., Randau, T. M., Hilgers, C., Haddouti, E. M., Masson, W., Gravius, S.,
et al. (2020). Molecular and functional phenotypes of human bone marrow-
derived mesenchymal stromal cells depend on harvesting techniques. Int. J.
Mol. Sci. 21:4382. doi: 10.3390/ijms21124382
Wang, R., Jiang, W., Zhang, L., Xie, S., Zhang, S., Yuan, S., et al. (2020).
Intra-articular delivery of extracellular vesicles secreted by chondrogenic
progenitor cells from MRL/MpJ superhealer mice enhances articular
cartilage repair in a mouse injury model. Stem Cell Res. Ther. 11:93.
doi: 10.1186/s13287-020-01594-x
Wang, Y., Yu, D., Liu, Z., Zhou, F., Dai, J., Wu, B., et al. (2017). Exosomes from
embryonic mesenchymal stem cells alleviate osteoarthritis through balancing
synthesis and degradation of cartilage extracellular matrix. Stem Cell Res. Ther.
8:189. doi: 10.1186/s13287-017-0632-0
Weilner, S., Schraml, E., Wieser, M., Messner, P., Schneider, K., Wassermann, K.,
et al. (2016). Secreted microvesicular miR-31 inhibits osteogenic differentiation
of mesenchymal stem cells. Aging Cell 15, 744–754. doi: 10.1111/acel.12484
Weng, Y., Sui, Z., Shan, Y., Hu, Y., Chen, Y., Zhang, L., et al. (2016).
Effective isolation of exosomes with polyethylene glycol from cell culture
supernatant for in-depth proteome profiling. The Analyst. 141, 4640–4646.
doi: 10.1039/C6AN00892E
Withrow, J., Murphy, C., Liu, Y., Hunter, M., Fulzele, S., and Hamrick, M. W.
(2016). Extracellular vesicles in the pathogenesis of rheumatoid arthritis and
osteoarthritis. Arthritis Res. Ther. 18:286. doi: 10.1186/s13075-016-1178-8
Witwer, K. W., Van Balkom, B. W. M., Bruno, S., Choo, A., Dominici, M.,
Gimona, M., et al. (2019). Defining mesenchymal stromal cell (MSC)-derived
small extracellular vesicles for therapeutic applications. J. Extracell. Vesicles
8:1609206. doi: 10.1080/20013078.2019.1609206
Wong, K. L., Zhang, S., Wang, M., Ren, X., Afizah, H., Lai, R. C., et al. (2020).
Intra-articular injections of mesenchymal stem cell exosomes and hyaluronic
acid improve structural and mechanical properties of repaired cartilage in
a rabbit model. Arthroscopy 36, 2215–2228.e2212. doi: 10.1016/j.arthro.2020.
03.031
Woo, C. H., Kim, H. K., Jung, G. Y., Jung, Y. J., Lee, K. S., Yun, Y.
E., et al. (2020). Small extracellular vesicles from human adipose-derived
stem cells attenuate cartilage degeneration. J. Extracell. Vesicles 9:1735249.
doi: 10.1080/20013078.2020.1735249
Wu, M., Ouyang, Y., Wang, Z., Zhang, R., Huang, P. H., Chen, C.,
et al. (2017). Isolation of exosomes from whole blood by integrating
acoustics and microfluidics. Proc. Natl. Acad. Sci. U.S.A. 114, 10584–10589.
doi: 10.1073/pnas.1709210114
Wu, X., Liu, Z., Hu, L., Gu, W., and Zhu, L. (2018). Exosomes derived from
endothelial progenitor cells ameliorate acute lung injury by transferring miR-
126. Exp. Cell Res. 370, 13–23. doi: 10.1016/j.yexcr.2018.06.003
Wu, Y., Deng, W., and Klinke, D. J. (2015). Exosomes: improved methods to
characterize their morphology, RNA content, and surface protein biomarkers.
Analyst 140, 6631–6642. doi: 10.1039/C5AN00688K
Xie, H., Wang, Z., Zhang, L., Lei, Q., Zhao, A., Wang, H., et al. (2017).
Extracellular vesicle-functionalized decalcified bone matrix scaffolds with
enhanced pro-angiogenic and pro-bone regeneration activities. Sci. Rep.
7:45622. doi: 10.1038/srep45622
Xu, H. J., Liao, W., Liu, X. Z., Hu, J., Zou, W. Z., Ning, Y., et al. (2019a). Down-
regulation of exosomal microRNA-224-3p derived from bone marrow-derived
mesenchymal stem cells potentiates angiogenesis in traumatic osteonecrosis of
the femoral head. FASEB J. 33, 8055–8068. doi: 10.1096/fj.201801618RRR
Xu, X., Lai, Y., and Hua, Z. C. (2019b). Apoptosis and apoptotic body:
disease message and therapeutic target potentials. Biosci. Rep. 39:BSR20180992.
doi: 10.1042/BSR20180992
Xue, C., Shen, Y., Li, X., Li, B., Zhao, S., Gu, J., et al. (2018). Exosomes
derived from hypoxia-treated human adipose mesenchymal stem cells enhance
angiogenesis through the PKA signaling pathway. Stem Cells Dev. 27, 456–465.
doi: 10.1089/scd.2017.0296
Yan, I. K., Shukla, N., Borrelli, D. A., and Patel, T. (2018). Use of a hollow fiber
bioreactor to collect extracellular vesicles from cells in culture. Methods Mol.
Biol. 1740, 35–41. doi: 10.1007/978-1-4939-7652-2_4
Yang, B. C., Kuang, M. J., Kang, J. Y., Zhao, J., Ma, J. X., and Ma, X. L.
(2020). Human umbilical cord mesenchymal stem cell-derived exosomes
act via the miR-1263/Mob1/Hippo signaling pathway to prevent apoptosis
in disuse osteoporosis. Biochem. Biophys. Res. Commun. 524, 883–889.
doi: 10.1016/j.bbrc.2020.02.001
Yavropoulou, M. P., Anastasilakis, A. D., Makras, P., Tsalikakis, D. G., Grammatiki,
M., and Yovos, J. G. (2017). Expression of microRNAs that regulate bone
turnover in the serum of postmenopausal women with low bone mass and
vertebral fractures. Eur. J. Endocrinol. 176, 169–176. doi: 10.1530/EJE-16-
0583
Yoon, S., Kovalenko, A., Bogdanov, K., and Wallach, D. (2017). MLKL,
the protein that mediates necroptosis, also regulates endosomal
trafficking and extracellular vesicle generation. Immunity 47, 51–65.e57.
doi: 10.1016/j.immuni.2017.06.001
Zargarian, S., Shlomovitz, I., Erlich, Z., Hourizadeh, A., Ofir-Birin, Y., Croker,
B. A., et al. (2017). Phosphatidylserine externalization, “necroptotic bodies”
release, and phagocytosis during necroptosis. PLoS Biol. 15:e2002711.
doi: 10.1371/journal.pbio.2002711
Zhang, B., Wu, X., Zhang, X., Sun, Y., Yan, Y., Shi, H., et al. (2015a).
Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis
through the Wnt4/beta-catenin pathway. Stem Cells Transl. Med. 4, 513–522.
doi: 10.5966/sctm.2014-0267
Zhang, B., Yeo, R. W. Y., Lai, R. C., Sim, E. W. K., Chin, K. C., and Lim, S.
K. (2018a). Mesenchymal stromal cell exosome-enhanced regulatory T-cell
production through an antigen-presenting cell-mediated pathway. Cytotherapy
20, 687–696. doi: 10.1016/j.jcyt.2018.02.372
Zhang, B., Yin, Y., Lai, R. C., Tan, S. S., Choo, A. B., and Lim, S. K. (2014).
Mesenchymal stem cells secrete immunologically active exosomes. Stem Cells
Dev. 23, 1233–1244. doi: 10.1089/scd.2013.0479
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org 27 January 2021 | Volume 8 | Article 624096
Herrmann et al. EVs in Musculoskeletal Diseases
Zhang, C., Xu, S., Zhang, S., Liu, M., Du, H., Sun, R., et al. (2019).
Ageing characteristics of bone indicated by transcriptomic and exosomal
proteomic analysis of cortical bone cells. J. Orthop. Surg. Res. 14:129.
doi: 10.1186/s13018-019-1163-4
Zhang, G. Y., Zou, X. Y., Huang, Y. Q., Wang, F., Miao, S., Liu, G. H., et al. (2016a).
Mesenchymal stromal cell-derived extracellular vesicles protect against acute
kidney injury through anti-oxidation by enhancingNrf2/ARE activation in rats.
Kidney Blood Press R 41, 119–128. doi: 10.1159/000443413
Zhang, J., Chen, C., Hu, B., Niu, X., Liu, X., Zhang, G., et al. (2016b). Exosomes
derived from human endothelial progenitor cells accelerate cutaneous wound
healing by promoting angiogenesis through Erk1/2 signaling. Int. J. Biol. Sci.
12, 1472–1487. doi: 10.7150/ijbs.15514
Zhang, J., Guan, J., Niu, X., Hu, G., Guo, S., Li, Q., et al. (2015b). Exosomes released
from human induced pluripotent stem cells-derived MSCs facilitate cutaneous
wound healing by promoting collagen synthesis and angiogenesis. J. Transl.
Med. 13:49. doi: 10.1186/s12967-015-0417-0
Zhang, J., Liu, X., Li, H., Chen, C., Hu, B., Niu, X., et al. (2016c).
Exosomes/tricalcium phosphate combination scaffolds can enhance bone
regeneration by activating the PI3K/Akt signaling pathway. Stem Cell Res. Ther.
7:136. doi: 10.1186/s13287-016-0391-3
Zhang, S., Chu, W. C., Lai, R. C., Lim, S. K., Hui, J. H. P., and Toh, W.
S. (2016d). Exosomes derived from human embryonic mesenchymal stem
cells promote osteochondral regeneration. Osteoarthr. Cartil. 24, 2135–2140.
doi: 10.1016/j.joca.2016.06.022
Zhang, S. P., Chuah, S. J., Lai, R. C., Hui, J. H. P., Lim, S. K., and Toh, W. S.
(2018b). MSC exosomes mediate cartilage repair by enhancing proliferation,
attenuating apoptosis and modulating immune reactivity. Biomaterials 156,
16–27. doi: 10.1016/j.biomaterials.2017.11.028
Zhao, H., Jaffer, T., Eguchi, S., Wang, Z., Linkermann, A., and Ma, D. (2015). Role
of necroptosis in the pathogenesis of solid organ injury. Cell Death Dis. 6:e1975.
doi: 10.1038/cddis.2015.316
Zhu, Y., Wang, Y., Zhao, B., Niu, X., Hu, B., Li, Q., et al. (2017). Comparison of
exosomes secreted by induced pluripotent stem cell-derivedmesenchymal stem
cells and synovial membrane-derivedmesenchymal stem cells for the treatment
of osteoarthritis. Stem Cell Res. Ther. 8:64. doi: 10.1186/s13287-017-0510-9
Zhu, Y., Zhang, J., Hu, X., Wang, Z., Wu, S., and Yi, Y. (2020). Extracellular
vesicles derived from human adipose-derived stem cells promote the exogenous
angiogenesis of fat grafts via the let-7/AGO1/VEGF signalling pathway. Sci.
Rep. 10:5313. doi: 10.1038/s41598-020-62140-6
Zou, X., Gu, D., Xing, X., Cheng, Z., Gong, D., Zhang, G., et al. (2016). Human
mesenchymal stromal cell-derived extracellular vesicles alleviate renal ischemic
reperfusion injury and enhance angiogenesis in rats. Am. J. Transl. Res 8,
4289–4299.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Copyright © 2021 Herrmann, Diederichs, Melnik, Riegger, Trivanović, Li, Jenei-
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